<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chronic non‐invasive ventilation for chronic obstructive pulmonary disease - Raveling, T - 2021 | Cochrane Library</title> <meta content="Chronic non‐invasive ventilation for chronic obstructive pulmonary disease - Raveling, T - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002878.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chronic non‐invasive ventilation for chronic obstructive pulmonary disease - Raveling, T - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002878.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002878.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Chronic non‐invasive ventilation for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Tim Raveling" name="citation_author"/> <meta content="t.raveling@umcg.nl" name="citation_author_email"/> <meta content="Judith Vonk" name="citation_author"/> <meta content="Fransien M Struik" name="citation_author"/> <meta content="University of Groningen, University Medical Center Groningen" name="citation_author_institution"/> <meta content="Roger Goldstein" name="citation_author"/> <meta content="West Park Healthcare Centre, University of Toronto" name="citation_author_institution"/> <meta content="Huib AM Kerstjens" name="citation_author"/> <meta content="Peter J Wijkstra" name="citation_author"/> <meta content="Marieke L Duiverman" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD002878.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002878.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002878.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002878.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Disease Progression; Dyspnea; *Noninvasive Ventilation; *Pulmonary Disease, Chronic Obstructive [therapy]; Quality of Life; *Respiratory Insufficiency [etiology, therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002878.pub3&amp;doi=10.1002/14651858.CD002878.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002878\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002878\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002878.pub3",title:"Chronic non\\u2010invasive ventilation for chronic obstructive pulmonary disease",firstPublishedDate:"Aug 9, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002878.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002878.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002878.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002878.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002878.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002878.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002878.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002878.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002878.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002878.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7615 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002878.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0124"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/appendices#CD002878-sec-0129"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/supinfo/CD002878StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/supinfo/CD002878StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chronic non‐invasive ventilation for chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tim Raveling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0005">Judith Vonk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0006">Fransien M Struik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0007">Roger Goldstein</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0008">Huib AM Kerstjens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0009">Peter J Wijkstra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information#CD002878-cr-0010">Marieke L Duiverman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information/en#CD002878-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002878.pub3">https://doi.org/10.1002/14651858.CD002878.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002878-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002878-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002878-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002878-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002878-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002878-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002878-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002878-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002878-abs-0001" lang="en"> <section id="CD002878-sec-0001"> <h3 class="title" id="CD002878-sec-0001">Background</h3> <p>Chronic non‐invasive ventilation (NIV) is increasingly being used to treat people with COPD who have respiratory failure, but the evidence supporting this treatment has been conflicting. </p> </section> <section id="CD002878-sec-0002"> <h3 class="title" id="CD002878-sec-0002">Objectives</h3> <p>To assess the effects of chronic non‐invasive ventilation at home via a facial mask in people with COPD, using a pooled analysis of IPD and meta‐analysis. </p> </section> <section id="CD002878-sec-0003"> <h3 class="title" id="CD002878-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Register of Trials, MEDLINE, Embase, PsycINFO, CINAHL, AMED, proceedings of respiratory conferences, clinical trial registries and bibliographies of relevant studies. We conducted the latest search on 21 December 2020. </p> </section> <section id="CD002878-sec-0004"> <h3 class="title" id="CD002878-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing chronic NIV for at least five hours per night for three consecutive weeks or more (in addition to standard care) versus standard care alone, in people with COPD. Studies investigating people initiated on NIV in a stable phase and studies investigating NIV commenced after a severe COPD exacerbation were eligible, but we reported and analysed them separately. The primary outcomes were arterial blood gases, health‐related quality of life (HRQL), exercise capacity (stable COPD) and admission‐free survival (post‐exacerbation COPD). Secondary outcomes for both populations were: lung function, COPD exacerbations and admissions, and all‐cause mortality. For stable COPD, we also reported respiratory muscle strength, dyspnoea and sleep efficiency. </p> </section> <section id="CD002878-sec-0005"> <h3 class="title" id="CD002878-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. After inclusion of a study, we requested the IPD. We analysed continuous and time‐to‐event data using linear‐ and cox‐regression mixed‐effect models with a random effect on study level. We analysed dichotomous IPD using generalised estimating equations. We adjusted all models for age and sex. We assessed changes in outcomes after three and 12 months.  We also conducted a meta‐analysis on aggregated trial data. </p> </section> <section id="CD002878-sec-0006"> <h3 class="title" id="CD002878-sec-0006">Main results</h3> <p>We included 14 new RCTs in this review update, in addition to the seven previously included. Seventeen studies investigated chronic NIV in stable COPD and four studies investigated chronic NIV commenced after a severe COPD exacerbation. Three studies compared NIV to sham continuous positive airway pressure (2 to 4 cmH<sub>2</sub>O). Seven studies used a nasal mask, one study used an oronasal mask and eight studies used both interfaces. Five studies did not report the interface. The majority of trials (20/21) were at high risk of performance bias due to an unblinded design. We considered 11 studies to have a low risk of selection bias and 13 to have a low risk of attrition bias. We collected and analysed the IPD from 13 stable COPD studies (n = 778, 68% of the participants included) and from three post‐exacerbation studies (n = 364, 96% of the participants included). </p> <p>In the stable COPD group, NIV probably results in a minor benefit on the arterial partial pressure of oxygen (PaO<sub>2</sub>) after three months (adjusted mean difference (AMD) 0.27 kPa, 95% CI 0.04 to 0.49; 9 studies, 271 participants; moderate‐certainty evidence), but there was little to no benefit at 12 months (AMD 0.09 kPa, 95% CI ‐0.23 to 0.42; 3 studies, 171 participants; low‐certainty evidence). The arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) was reduced in participants allocated to NIV after three months (AMD ‐0.61 kPa, 95% CI ‐0.77 to ‐0.45; 11 studies, 475 participants; high‐certainty evidence) and persisted up to 12 months (AMD ‐0.42 kPa, 95% CI ‐0.68 to ‐0.16; 4 studies, 232 participants; high‐certainty evidence).  </p> <p>Exercise capacity was measured with the 6‐minute walking distance (minimal clinical important difference: 26 m). There was no clinically relevant effect of NIV on exercise capacity (<b>3 months: </b> AMD 15.5 m, 95% CI ‐0.8 to 31.7; 8 studies, 330 participants; low‐certainty evidence; <b>12 months:</b> AMD 26.4 m, 95% CI ‐7.6 to 60.5; 3 studies, 134 participants; very low‐certainty evidence). HRQL was measured with the Severe Respiratory Insufficiency and the St. Georges's Respiratory Questionnaire and may be improved by NIV, but only after three months (<b>3 months:</b> standardised mean difference (SMD) 0.39, 95% CI 0.15 to 0.62; 5 studies, 259 participants; very low‐certainty evidence; <b>12 months:</b> SMD 0.15, 95% CI ‐0.13 to 0.43; 4 studies, 200 participants; very low‐certainty evidence). Lastly, the risk for all‐cause mortality is likely reduced by NIV (adjusted hazard ratio (AHR) 0.75, 95% CI 0.58 to 0.97; 3 studies, 405 participants; moderate‐certainty evidence). </p> <p>In the post‐exacerbation COPD group, there was little to no benefit on the PaO<sub>2</sub> after three months, but there may be a slight decrease after 12 months (<b>3 months:</b> AMD ‐0.10 kPa, 95% CI ‐0.65 to 0.45; 3 studies, 234 participants; low‐certainty evidence; <b>12 months:</b> ‐0.27 kPa, 95% CI ‐0.86 to 0.32, 3 studies; 170 participants; low‐certainty evidence). The PaCO<sub>2</sub> was reduced by NIV at both three months (AMD ‐0.40 kPa, 95% CI ‐0.70 to ‐0.09; 3 studies, 241 participants; moderate‐certainty evidence) and 12 months (AMD ‐0.52 kPa, 95% CI ‐0.87 to ‐0.18; 3 studies, 175 participants; high‐certainty evidence). NIV may have little to no benefit on HRQL (<b>3 months:</b> SMD 0.25, 95% CI ‐0.01 to 0.51; 2 studies, 219 participants; very low‐certainty evidence; <b>12 months: </b>SMD 0.25, 95% ‐0.06 to 0.55; 2 studies, 164 participants; very low‐certainty evidence). Admission‐free survival seems improved with NIV (AHR 0.71, 95% CI 0.54 to 0.94; 2 studies, 317 participants; low‐certainty evidence), but the risk for all‐cause mortality does not seem to improve (AHR 0.97, 95% CI 0.74 to 1.28; 2 studies, 317 participants; low‐certainty evidence). </p> </section> <section id="CD002878-sec-0007"> <h3 class="title" id="CD002878-sec-0007">Authors' conclusions</h3> <p>Regardless of the timing of initiation, chronic NIV improves daytime hypercapnia. In addition, in stable COPD, survival seems to be improved and there might be a short term HRQL benefit. In people with persistent hypercapnia after a COPD exacerbation, chronic NIV might prolong admission‐free survival without a beneficial effect on HRQL. </p> <p>In stable COPD, future RCTs comparing NIV to a control group receiving standard care might no longer be warranted, but research should focus on identifying participant characteristics that would define treatment success. Furthermore, the optimal timing for initiation of NIV after a severe COPD exacerbation is still unknown. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002878-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002878-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002878-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002878-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002878-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002878-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002878-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002878-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002878-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002878-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002878-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002878-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002878-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002878-abs-0002" lang="en"> <h3>Non‐invasive ventilation (ventilators) used at night by people with chronic obstructive pulmonary disease (COPD) </h3> <p><b>Background:</b> Non‐invasive ventilation (NIV) is a method to assist or replace spontaneous breathing (or normal breathing) with the aid of a machine called a ventilator, using a mask fitted over the nose or both the nose and mouth. NIV can be used chronically (long‐term) at the person's home if they have levels of carbon dioxide in their blood that are persistently too high. We wanted to discover if using chronic NIV at home during the night alongside standard therapy was better or worse than standard therapy alone in people with chronic obstructive pulmonary disease (COPD) who have raised carbon dioxide levels. In 2002 and 2013, we published our original Cochrane Reviews investigating this. It is important to check if new studies have been done that could be added to the existing studies of the original review and would change the findings. </p> <p><b>What is individual participant data:</b> In this review we used individual participant data (IPD). This means that we attempted to collect original research data for each person who had participated in the original studies by requesting these individuals' data from the researcher who performed the study. We used IPD as this offers a greater chance to detect changes between groups of participants and enable the investigation of additional hypotheses. We used the IPD to perform our calculations. </p> <p><b>Review question:</b> What is the effect of chronic NIV in people with COPD on blood gases (oxygen and carbon dioxide), exercise capacity, quality of life, lung function, respiratory muscle function, COPD exacerbations and admissions, and survival? </p> <p><b>Study characteristics:</b> The evidence is current to 21 December 2020. This review update identified 14 new studies in addition to those already in the review, so in total we included 21 studies. Ten of the studies looked at people in a stable phase (stable COPD) and four studies looked at people shortly after a COPD hospital admission (post‐exacerbation COPD). All studies included men and women. For our analyses, we used data from 778 people with stable COPD and 364 people with post‐exacerbation COPD. </p> <p><b>Results:</b> In all people with COPD who had raised levels of carbon dioxide, chronic NIV for three and 12 months improved blood gases. In stable COPD, chronic NIV also might have improved quality of life, and survival seemed to be better compared to people who were treated with standard care only. There was no relevant benefit of NIV on exercise capacity. People using chronic NIV after a COPD admission experienced less benefit; carbon dioxide levels decreased, the time to the next hospital admission might have been longer when treated with NIV but quality of life and survival were not affected by chronic NIV.  </p> <p><b>Certainty of the results: </b>Our confidence in the certainty (according to GRADE criteria) is good when looking at the blood gases. For the other outcomes, the certainty of the evidence is moderate to very low because the participants and the researcher were aware of the treatment the people received, and due to a wide range in the observed effect. This means that further research might change the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002878-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002878-sec-0124"></div> <h3 class="title" id="CD002878-sec-0125">Implications for practice</h3> <section id="CD002878-sec-0125"> <p>The results of this systematic review and individual participant data (IPD) analysis provide sufficient evidence for the routine application of chronic NIV in people with severe chronic obstructive pulmonary disease (COPD) who have chronic hypercapnic respiratory failure (CHRF), while its place remains uncertain for people who remain hypercapnic shortly after a severe COPD exacerbation. The benefits and goals of chronic non‐invasive ventilation (NIV) seem to differ between different COPD populations. For people initiated in a stable clinical state, significant and relevant improvements in diurnal hypercapnia can be achieved, and oxygenation, health‐related quality of life (HRQL) and all‐cause mortality might improve. In contrast, people who remain hypercapnic after a severe COPD exacerbation seem to benefit mostly in terms of a reduction in hypercapnia, and a prolonged time to readmission or death, but without relevant improvements in HRQL. Evidence also suggests that the effect of NIV on gas exchange is largest when the NIV is applied with sufficiently high pressures and for at least five hours of NIV use per night. </p> <p>Currently, the application of chronic NIV in people with COPD varies greatly between different healthcare providers (<a href="./references#CD002878-bbs2-0042" title="CrimiC , NotoA , PrinciP , CuvelierA , MasaJF , SimondsA , et al. Domiciliary non-invasive ventilation in COPD: an international survey of indications and practices. COPD2016;13(4):483-90. [DOI: 10.3109/15412555.2015.1108960]">Crimi 2016</a>). Considering the results of the participant‐centred outcomes of this review, reluctance towards the initiation of NIV in stable hypercapnic COPD may no longer be warranted, whilst the application of chronic NIV post‐exacerbation can be discussed. Consistent with the guideline recommendations of the European Respiratory Society and the American Thoracic Society, the findings of this review support the application of this treatment in people with severe end‐stage COPD (<a href="./references#CD002878-bbs2-0047" title="ErganB , OczkowskiS , RochwergB , CarlucciA , ChatwinM , CliniE , et al. European Respiratory Society Guideline on Long-term Home Non-Invasive Ventilation for Management of Chronic Obstructive Pulmonary Disease. European Respiratory Journal2019;57:1901003. [DOI: 10.1183/13993003.01003-2019]">Ergan 2019</a>; <a href="./references#CD002878-bbs2-0054" title="MacreaM , OczkowskiS , RochwergB , BransonRD , CelliB , Coleman JM 3rd. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease.   An official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine2020;202(4):e74-e87. [DOI: 10.1164/rccm.202006-2382ST]">Macrea 2020</a>). </p> </section> <h3 class="title" id="CD002878-sec-0126">Implications for research</h3> <section id="CD002878-sec-0126"> <p>Given that the certainty of the evidence on the participant‐centred outcomes is moderate to very low, there is a need for new randomised controlled trials (RCTs) that investigate chronic NIV in people with stable COPD to strengthen the evidence. For future studies it should be taken into consideration that these people are severely limited by their disease and have poor prognosis and a limited number of other treatment options. Therefore, ethical concerns might arise when withholding NIV from a control group. In contrast, there remains a need for additional RCTs that investigate chronic NIV shortly after a severe exacerbation. Nevertheless, not all people eventually benefit from NIV, and the initiation of this treatment can be challenging and stressful. Therefore, future studies may focus on the identification of the person with COPD who is most likely to benefit from this treatment. Large observational studies may identify different COPD phenotypes based on individual and disease characteristics, and try to identify the underlying cause of chronic hypercapnic respiratory failure in the individual person. Furthermore, studies are needed to further elucidate what pathophysiological mechanisms are improved by NIV (and in what way), so that more goal‐directed therapy can be provided. The evidence regarding respiratory muscle functioning improvement is limited, as is the evidence regarding sleep quality improvement. Treatment targets are needed for the different phenotypes, and optimal criteria to start and continue NIV are to be identified, realising that these targets and criteria might differ substantially between different phenotypes. Lastly, the current aim of chronic NIV is to reduce the partial pressure of carbon dioxide (PaCO<sub>2</sub>) by improving nocturnal ventilation. Evidence that only this reduction is responsible for the improved outcomes is insufficient, and there is a need to unravel the mechanisms through which this intervention improves physiological and participant‐centred outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002878-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002878-sec-0008"></div> <div class="table" id="CD002878-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : stable COPD <b>Setting</b> : home treatment <b>Intervention</b> : NIV <b>Comparison</b>: Standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NIV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>‐0.07</b> kPa <sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.27 kPa higher</b><br/>(0.04 higher to 0.49 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV probably results in a slightly greater increase in arterial partial pressure of oxygen after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>‐0.06</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.09 kPa higher</b><br/>(0.23 lower to 0.42 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may result in little to no difference in arterial partial pressure of oxygen after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.17</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.61 kPa lower</b><br/>(0.77 lower to 0.45 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>475<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in the arterial partial pressure of carbon dioxide after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.05</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.42 kPa lower</b><br/>(0.68 lower to 0.16 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in arterial partial pressure of carbon dioxide after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in 6‐minute walking distance<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in 6‐minute walking distance was <b>16.0</b> metres </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>15.5 metres higher</b><br/>(0.8 lower to 31.7 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>330<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>d,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence suggests that chronic NIV results in little to no difference on the 6‐minute walking distance test. Sensitivity analysis limited to high‐quality studies suggest a significant benefit; however, this treatment estimate does not reach the minimal important difference of 26m. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in 6‐minute walking distance<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in 6‐minute walking distance was <b>‐10.7</b> metres </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>26.4 metres higher</b><br/>(7.6 lower to 60.5 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>g,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase the 6‐minute walking distance but the evidence is very uncertain. This treatment estimate reaches the clinical relevance of 26m in this specific population. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 3 months <sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.39 SD higher</b><br/>(0.15 higher to 0.62 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>d,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase health‐related quality of life after 3 months but the evidence is very uncertain. Considering the standard deviation of 12 units on the SRI, the observed SMD does seem to reach the minimal important difference of approximately 5 points in this specific population. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 12 months <sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.15 SD higher</b><br/>(0.13 lower to 0.43 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>h,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence is very uncertain about the effect of chronic NIV on health‐related quality of life after 12 months. Considering a standard deviation of 12.2 units on the SRI, the observed SMD does not seem to reach the minimal important difference of approximately 5 points. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality<br/>follow up: median 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.75</b><br/>(0.58 to 0.97)<br/>[All‐cause mortality] <sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>405<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Chronic NIV likely reduces all‐cause mortality (number needed to treat for an additional beneficial outcome 14, 95% CI 8 to 120). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>655 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>550 per 1000</b><br/>(461 to 644) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>SMD:</b> Standardised mean difference; <b>HR:</b> Hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417569665332318026" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417569665332318026</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> For the risk with standard care, we calculated an absolute difference in the outcome between the baseline measurement and both follow‐up measurements (3 and 12 months)<br/><b>b.</b> The mean difference was obtained from the pooled individual participant data, and was adjusted for age and sex. <br/><b>c.</b> Not downgraded; although the participants and investigators were not blinded in the majority of the trials, this is unlikely to affect blood gases and survival.<br/><b>d.</b> Downgraded by one for serious imprecision; the CI includes the possibility of no (relevant) benefit and of a substantial benefit.<br/><b>e.</b> Downgraded by one due to serious imprecision: the CI includes the possibility of harm and of a large substantial benefit. <br/><b>f.</b> Inconsistency not downgraded; although substantial heterogeneity was observed (P = 0.001, I2 = 65%), this could be explained by the subgroup analysis.<br/><b>g.</b> Downgraded by one due to high risk of bias; the majority of the trials did not blind participants and investigators/personnel to the treatment allocation.<br/><b>h.</b> Downgraded by two due to serious imprecision: the CI includes the possibility of harm and of a large substantial benefit. <br/><b>i.</b> SRI: Severe Respiratory Insufficiency questionnaire; SGRQ: St. George's Respiratory Questionnaire<br/><b>j.</b> Downgraded by one due to high risk of bias; no trials blinded participants and investigators/personnel to the treatment allocation.<br/><b>k.</b> The hazard ratio was obtained from the pooled individual participant data, and was adjusted for age, sex and the baseline arterial pressure of carbon dioxide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002878-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : post‐exacerbation COPD <b>Setting</b> : home treatment <b>Intervention</b> : NIV <b>Comparison</b>: Standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NIV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>0.19</b> kPa <sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.1 kPa lower</b><br/>(0.65 lower to 0.45 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence suggests that chronic NIV results in little to no difference in arterial partial pressure of oxygen after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>0.48</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.27 kPa lower</b><br/>(0.86 lower to 0.32 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may result in a slight reduction in arterial partial pressure of oxygen after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.59</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.4 kPa lower</b><br/>(0.7 lower to 0.09 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV likely reduces the arterial partial pressure of carbon dioxide after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.61</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.52 kPa lower</b><br/>(0.87 lower to 0.18 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in the arterial partial pressure of carbon dioxide after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 3 months <sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.25 SD higher</b><br/>(0.01 lower to 0.51 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase/have little to no effect on health‐related quality of life after 3 months but the evidence is very uncertain. Considering a standard deviation of 11.2 on the SRI, the SMD does not seem to reach the minimal important difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 12 months <sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.25 SD higher</b><br/>(0.06 lower to 0.55 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase/have little to no effect on health‐related quality of life after 12 months but the evidence is very uncertain. Considering a standard deviation of 11.9 on the SRI, the SMD does not seem to reach the minimal important difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Admission‐free survival<br/>follow up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.71</b><br/>(0.54 to 0.94)<br/>[readmission or death] <sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>317<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>e,</sup><sup>i,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The evidence suggests chronic NIV improves admission‐free survival (number needed to treat for an additional beneficial outcome 12, 95% CI 7 to 61). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>458 per 1000</b><br/>(356 to 552) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality<br/>follow up: median 21 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.97</b><br/>(0.74 to 1.28)<br/>[All‐cause mortality] <sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>318<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The evidence suggests that chronic NIV does not improve all‐cause mortality.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>631 per 1000</b><br/>(532 to 731) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>SMD:</b> Standardised mean difference; <b>HR:</b> Hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417570213828006491" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417570213828006491</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> For the risk with standard care, we calculated an absolute difference in the outcome between the baseline measurement and both follow‐up measurements (3 and 12 months).<br/><b>b.</b> The mean difference was obtained from the pooled individual participant data, and was adjusted for age and sex.<br/><b>c.</b> Not downgraded; although the participants and investigators were not blinded in the majority of the trials, this is unlikely to affect blood gases and survival.<br/><b>d.</b> Downgraded by two due to serious imprecision: the CI includes the possibility of significant harm and of a substantial benefit.<br/><b>e.</b> Downgraded by one due to serious imprecision: the CI includes the possibility of no (relevant) benefit and of a substantial benefit.<br/><b>f.</b> SRI: Severe Respiratory Insufficiency questionnaire; SGRQ: St. George's Respiratory Questionnaire<br/><b>g.</b> Downgraded by two due to high risk of bias; no trials blinded participants and investigators/personnel to the treatment allocation.<br/><b>h.</b> The hazard ratio was obtained from the pooled individual participant data, and was adjusted for age sex, baseline arterial partial pressure of carbon dioxide and number of COPD hospitalisations. <br/><b>i.</b> Downgraded by one; the majority of the participants were unblinded which could affect the likelyhood of attending the emergency department. Other domains low risk of bias<br/><b>j.</b> Inconsistency not downgraded; although substantial heterogeneity was observed (P = 0.05, I2 = 75%), this heterogeneity might be explained by differences in participant selection and the timing of NIV. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002878-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002878-sec-0009"></div> <section id="CD002878-sec-0010"> <h3 class="title" id="CD002878-sec-0010">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable but incurable disease that is characterised by chronic airflow obstruction due to airway disease and lung parenchymal destruction (<a href="./references#CD002878-bbs2-0048" title="Global Strategy for the Diagnosis, Management and Prevention of COPD 2021. Global Initiative for Chronic Obstructive Lung Disease (GOLD). goldcopd.org/2021-gold-reports/2021.">GOLD 2021</a>). In 2016, COPD affected over 251 million people worldwide, and is currently the third leading cause of death, claiming approximately 3.2 million lives in 2015 (<a href="./references#CD002878-bbs2-0073" title="World Health Organization - Factsheet Chronic Obstructive Pulmonary Disease. www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (accessed prior to 12 February 2021).">WHO 2020</a>). In general, the treatment of COPD is directed at slowing down the progression of its natural history, symptom alleviation, improvement in daily functioning and health‐related quality of life (HRQL). Many patients experience exacerbations of their COPD, defined as an acute worsening of symptoms and requiring additional treatment (<a href="./references#CD002878-bbs2-0048" title="Global Strategy for the Diagnosis, Management and Prevention of COPD 2021. Global Initiative for Chronic Obstructive Lung Disease (GOLD). goldcopd.org/2021-gold-reports/2021.">GOLD 2021</a>). Exacerbations are a major problem as patients who experience frequent exacerbations, especially those requiring hospitalisation, experience accelerated deterioration of their condition, a faster decline in lung function, a high risk of rehospitalisation and a higher mortality risk (<a href="./references#CD002878-bbs2-0043" title="DonaldsonGC , SeemungalTA , BhowmikA , WedzichaJA . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.. Thorax2002;57(10):847-52. [DOI: 10.1136/thorax.57.10.847]">Donaldson 2002</a>; <a href="./references#CD002878-bbs2-0052" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [DOI: 10.1056/NEJMoa0909883]">Hurst 2010</a>). Therefore, treatment options that reduce the risk of exacerbations are particularly attractive. As the disease progresses to an advanced stage, people experience severe symptoms of dyspnoea and are usually severely disabled in activities of daily living. In some people with advanced disease, chronic hypercapnic respiratory failure (CHRF) may follow with related symptoms, such as morning headache, and fragmented and un‐refreshing sleep resulting in chronic fatigue and daytime sleepiness (<a href="./references#CD002878-bbs2-0078" title="WindischW , StorreJH , KöhnleinT . Nocturnal non-invasive positive pressure ventilation for COPD. Expert Review in Respiratory Medicine2015;9(3):295-308. [DOI: 10.1586/17476348.2015.1035260]">Windisch 2015</a>). At this advanced stage, treatment options are urgently needed but unfortunately still limited (<a href="./references#CD002878-bbs2-0071" title="vanDijkM , GanCT , KosterTD , WijkstraPJ , SlebosDJ , KerstjensHA , et al. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Research2020;6(3):00322-2019. [DOI: 10.1183/23120541.00322-2019]">van Dijk 2020</a>). </p> </section> <section id="CD002878-sec-0011"> <h3 class="title" id="CD002878-sec-0011">Description of the intervention</h3> <p>Non‐invasive ventilation (NIV) is the application of ventilatory support through a non‐invasive interface, usually a nasal or oronasal mask. NIV is currently applied as evidence‐based therapy for COPD patients admitted to hospital with acute hypercapnic respiratory failure (AHRF) due to an exacerbation. In this situation, NIV reduces the likelihood of endotracheal intubation, complications associated with treatment, duration of hospital stay and in‐hospital mortality (<a href="./references#CD002878-bbs2-0057" title="OsadnikCR , TeeVS , Carson‐ChahhoudKV , PicotJ , WedzichaJA , SmithBJ . Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD004104. [DOI: 10.1002/14651858.CD004104.pub4]">Osadnik 2017</a>). During an exacerbation, NIV is often applied intermittently or continuously for a few days to overcome the acute life‐threatening respiratory failure, after which the person is weaned from ventilation and NIV can be stopped. Chronic NIV, however, entails the long‐term use of nocturnal NIV. There has been much discussion about the need for chronic NIV in stable COPD, mainly because the earlier trials published conflicting results (<a href="./references#CD002878-bbs2-0065" title="RossiA , HillNS . Non invasive ventilation has (not) been shown to be ineffective in stable COPD. American Journal of Respiratory and Critical Care Medicine2000;161:688-91.">Rossi 2000</a>). The previous version of this Cochrane Review, which investigated chronic NIV in people with stable COPD, did not find any significant benefits on gas exchange, exercise capacity, lung function or HRQL (<a href="./references#CD002878-bbs2-0080" title="StruikFM , LacasseY , GoldsteinR , KerstjensHA , WijkstraPJ . Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease (Review). Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD002878. [DOI: 10.1002/14651858.CD002878.pub2]">Struik 2013</a>). However, it did find that a subgroup of people with more severe hypercapnia was more likely to benefit, especially when treated with higher inspiratory pressures and when NIV was used for more than five hours per day (<a href="./references#CD002878-bbs2-0069" title="StruikFM , LacasseY , GoldsteinRS , KerstjensHA , WijkstraPJ . Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respiratory Medicine2014;108(2):329-37. [DOI: 10.1016/j.rmed.2013.10.007]">Struik 2014</a>). </p> </section> <section id="CD002878-sec-0012"> <h3 class="title" id="CD002878-sec-0012">How the intervention might work</h3> <p>Several theories exist as to why chronic NIV may be beneficial in stable COPD. First, chronic nocturnal NIV ameliorates nocturnal hypoventilation. This effect is intended to persist during the daytime; improved lung mechanics, improved respiratory muscle function and resetting of the chemoresponsiveness might all contribute to a more advantageous breathing pattern, enabling the person to maintain the improved gas exchange during the day (<a href="./references#CD002878-bbs2-0046" title="ElliottMW , MulveyDA , MoxhamJ , GreenM , BranthwaiteMA . Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions. European Respiratory Journal1991;4(9):1044-52.">Elliott 1991</a>). Several studies have indicated that NIV probably stabilises forced expiratory volume in one second (FEV<sub>1</sub>) (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>); some observations indicate that NIV might also decrease residual volume (<a href="./references#CD002878-bbs2-0025" title="DiazO , GallardoJ , RamosJ , TorrealbaB , LisboaC . Non-invasive mechanical ventilation in severe stable hypercapnic COPD patients: a prospective randomised clinical trial. American Journal of Respiratory and Critical Care Medicine1999;159:A295. ">Diaz 1999</a>). The observation regarding FEV<sub>1</sub> is interesting as this was also observed without changes in static lung volume (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>), so might be caused by a different mechanism, possibly through the reduction of airway inflammation and oedema. It has also been postulated that NIV might rest chronically fatigued respiratory muscles. Periods of rest may lead to recovery of the inspiratory muscle function, thereby leading to an increased muscle strength and endurance capacity of the respiratory muscles during the daytime (<a href="./references#CD002878-bbs2-0039" title="AmbrosinoN , MontagnaT , NavaS , NegriA , BregaS , FracchiaC , et al. Short term effect of intermittent negative pressure ventilation in COPD patients with respiratory failure. European Respiratory Journal1990;3:502-8.">Ambrosino 1990</a>). Finally, NIV has been shown to improve sleep time and efficiency (<a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>), an effect that might be especially important for improving daily functioning and HRQL.  </p> </section> <section id="CD002878-sec-0013"> <h3 class="title" id="CD002878-sec-0013">Why it is important to do this review</h3> <p>Despite all these theoretical benefits, the added value of chronic NIV in people with stable COPD remains unclear and needs further investigation. This is the second update of a Cochrane Review on this topic, the first being published in 2002 and subsequently updated in 2013 (<a href="./references#CD002878-bbs2-0080" title="StruikFM , LacasseY , GoldsteinR , KerstjensHA , WijkstraPJ . Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease (Review). Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD002878. [DOI: 10.1002/14651858.CD002878.pub2]">Struik 2013</a>; <a href="./references#CD002878-bbs2-0081" title="WijkstraPJ , LacasseY , GuyattGH , GoldsteinRS . Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD002878. [DOI: 10.1002/14651858.CD002878]">Wijkstra 2002</a>). Since the 2013 update, more studies have been reported, including the large 2014 randomised controlled trial (RCT) by <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>, which showed improved gas exchange and HRQL, and a survival benefit with NIV compared to standard care alone. Also, the role of chronic NIV in the treatment of people with severe stable COPD has become more established with the publication of the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines on long‐term NIV in COPD (<a href="./references#CD002878-bbs2-0047" title="ErganB , OczkowskiS , RochwergB , CarlucciA , ChatwinM , CliniE , et al. European Respiratory Society Guideline on Long-term Home Non-Invasive Ventilation for Management of Chronic Obstructive Pulmonary Disease. European Respiratory Journal2019;57:1901003. [DOI: 10.1183/13993003.01003-2019]">Ergan 2019</a>; <a href="./references#CD002878-bbs2-0054" title="MacreaM , OczkowskiS , RochwergB , BransonRD , CelliB , Coleman JM 3rd. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease.   An official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine2020;202(4):e74-e87. [DOI: 10.1164/rccm.202006-2382ST]">Macrea 2020</a>). Additionally, since the last review update, important RCTs with conflicting results have been published that investigated the initiation of chronic NIV shortly after a severe COPD exacerbation with AHRF (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). It has been suggested that these conflicting results are due to differences in participant selection and timing of NIV initiation. Despite these conflicting results, it is common practice in many countries to initiate chronic NIV in this specific COPD population. These new trials justify the current update of the 2013 review, which in addition to stable COPD also includes trials which investigated chronic NIV following an exacerbation of COPD, as we realise this has become part of regular clinical care by many healthcare providers. </p> <p>As in the earlier versions of this review, we conducted a systematic review and a pooled analysis of individual participant data (IPD). We aimed to collect the original data of each participant from the trial authors for data checking, validation and re‐analysis. Compared to conventional meta‐analysis based on aggregated trial data, pooled analyses of IPD yields greater power and enables the investigation of additional hypotheses related to individual characteristics, for example within subgroups or treatment across trials. Although IPD reviews are regarded as the highest standard in systematic reviews, these reviews rely on the willingness of trial authors to share the IPD, which poses a threat to the review process. Potential risks might arise if trial authors do not agree to share the IPD as this could reduce the body of evidence. This could also introduce bias as the trials that do agree to share the IPD could differ from trials that did not agree, e.g. differ on the population or methodological approaches. To minimise this threat, we also conducted a meta‐analysis of aggregate trial data in addition to the analysis of IPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002878-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002878-sec-0014"></div> <p>To assess the effects of chronic non‐invasive ventilation at home via a facial mask in people with COPD, using a pooled analysis of IPD and meta‐analysis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002878-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002878-sec-0015"></div> <section id="CD002878-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002878-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs in participants with COPD comparing chronic NIV at home plus standard therapy with standard therapy alone. </p> <p>We differentiated between studies investigating chronic NIV in the following COPD populations: </p> <p> <ol id="CD002878-list-0001"> <li> <p>stable COPD: concerns studies of people with COPD initiated on chronic NIV in a stable clinical state; </p> </li> <li> <p>post‐exacerbation COPD: concerns studies of people with COPD initiated on chronic NIV following an exacerbation of COPD with acute respiratory failure. </p> </li> </ol> </p> </section> <section id="CD002878-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with COPD (a ratio of FEV<sub>1</sub> to forced vital capacity (FVC) &lt; 0.70), according to the most recent guideline of the Global initiative for chronic Obstructive Lung Disease at the time of writing (<a href="./references#CD002878-bbs2-0048" title="Global Strategy for the Diagnosis, Management and Prevention of COPD 2021. Global Initiative for Chronic Obstructive Lung Disease (GOLD). goldcopd.org/2021-gold-reports/2021.">GOLD 2021</a>). </p> </section> <section id="CD002878-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention of interest was NIV, applied through a facial mask, prescribed for at least five hours during the night and for at least three consecutive weeks. Participants also received their usual standard COPD therapy, which comprised supplementary oxygen, optimised medication or pulmonary rehabilitation or exercise programs. </p> <p>The intervention in the control group was standard therapy alone. The control group did not receive chronic NIV; sham treatment in the form of continuous positive airway pressure (without pressure support) was permitted. </p> </section> <section id="CD002878-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the following outcome measures with a short‐term follow‐up (up to three months) and a long‐term follow‐up (12 months). </p> <section id="CD002878-sec-0021"> <h5 class="title">Primary outcomes</h5> <p><b>Stable COPD</b> </p> <p> <ol id="CD002878-list-0002"> <li> <p>Change in daytime arterial blood gas tensions (partial pressure of oxygen (PaO<sub>2</sub>), partial pressure of carbon dioxide (PaCO<sub>2</sub>)) </p> </li> <li> <p>Change in exercise capacity, measured with the six‐minute walking distance (6MWD)</p> </li> <li> <p>Change in HRQL, measured with the Severe Respiratory Insufficiency questionnaire (SRI) (<a href="./references#CD002878-bbs2-0075" title="WindischW , FreidelK , SchucherB , BaumannH , WiebelM , MatthysH , et al. The Severe Respiratory Insufficiency (SRI) Questionnaire: a specific measure of health-related quality of life in patients receiving home mechanical ventilation. Journal of Clinical Epidemiology2003;56:752-9. [DOI: 10.1016/s0895-4356(03)00088-x]">Windisch 2003</a>) or the St George's Respiratory Questionnaire (SGRQ) (<a href="./references#CD002878-bbs2-0053" title="JonesPW , QuirkFH , BaveystockCM . The St George's Respiratory Questionnaire. Respiratory Medicine1991;85(Suppl B):25-31; discussion 33-7.">Jones 1991</a>) </p> </li> </ol> </p> <p><b>Post‐exacerbation COPD</b> </p> <p> <ol id="CD002878-list-0003"> <li> <p>Change in daytime arterial blood gas tensions (PaO<sub>2</sub> and PaCO<sub>2</sub>) </p> </li> <li> <p>Change in HRQL, measured with the SRI or the SGRQ</p> </li> <li> <p>Admission‐free survival, time to readmission or death of any cause</p> </li> </ol> </p> </section> <section id="CD002878-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p><b>Stable COPD</b> </p> <p> <ol id="CD002878-list-0004"> <li> <p>Change in lung function (FEV<sub>1</sub>, FVC and residual volume/total lung capacity (RV/%TLC)) </p> </li> <li> <p>Change in respiratory muscle function (maximal inspiratory pressure (PImax), maximal expiratory pressure (PEmax)) </p> </li> <li> <p>Change in dyspnoea (measured with the Transitional Dyspnoea Index (TDI) (<a href="./references#CD002878-bbs2-0056" title="MahlerDA , WeinbergDH , WellsCK , FeinsteinAR . The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest1984;85(6):751-8.">Mahler 1984</a>), or the (modified) Medical Research Council (MRC) dyspnoea scale) (<a href="./references#CD002878-bbs2-0040" title="BestallJC , PaulEA , GarrodR , GarnhamR , JonesPW , WedzichaJA . Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax1999;54(7):581-6.">Bestall 1999</a>) </p> </li> <li> <p>Change in sleep efficiency (percentage time asleep of total time in bed)</p> </li> <li> <p>Number of COPD exacerbations and hospital admissions, either self‐reported or documented</p> </li> <li> <p>All‐cause mortality, time to death of any cause</p> </li> </ol> </p> <p><b>Post exacerbation COPD</b> </p> <p> <ol id="CD002878-list-0005"> <li> <p>Change in lung function (FEV<sub>1</sub> and FVC) </p> </li> <li> <p>Number of COPD exacerbations and hospital admissions, either self‐reported or documented</p> </li> <li> <p>All‐cause mortality, time to death of any cause</p> </li> </ol> </p> </section> </section> </section> <section id="CD002878-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002878-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Register of Trials, which is maintained by the Information Specialist at the Cochrane Airways editorial base. The Register contains trial reports identified through searches of the following bibliographic databases: </p> <p> <ul id="CD002878-list-0006"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies (CRS); </p> </li> <li> <p>weekly searches of MEDLINE Ovid SP; 1946 to December 2020;</p> </li> <li> <p>weekly searches of Embase Ovid SP; 1974 to December 2020;</p> </li> <li> <p>monthly searches of PsycINFO Ovid SP; 1967 to December 2020;</p> </li> <li> <p>monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature); 1937 to December 2020; </p> </li> <li> <p>monthly searches of AMED EBSCO (Allied and Complementary Medicine); all years to December 2020; </p> </li> <li> <p>handsearches of the proceedings of major respiratory conferences.</p> </li> </ul> </p> <p>Full details of the search strategies used to maintain the Cochrane Airways Register of Trials are presented in <a href="./appendices#CD002878-sec-0130">Appendix 1</a>. </p> <p>The full search details of the previous versions of this review are presented in <a href="./appendices#CD002878-sec-0135">Appendix 2</a>. The search terms used for this update can be found in <a href="./appendices#CD002878-sec-0136">Appendix 3</a>. As some adjustments were made to the inclusion criteria, we conducted the search for this update with no date restrictions. We conducted this most recent search on 21 December 2020 without any language restrictions.  </p> <p>The current search additionally included the following trial registries; the World Health Organization International Clinical Trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (see <a href="./appendices#CD002878-sec-0136">Appendix 3</a>). </p> </section> <section id="CD002878-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the bibliographies of each RCT for additional papers that may have contained RCTs, and searched the reference lists of relevant clinical guidelines and systematic reviews for additional papers. We contacted authors of identified RCTs for other published and unpublished studies. </p> </section> </section> <section id="CD002878-sec-0026"> <h3 class="title" id="CD002878-sec-0026">Data collection and analysis</h3> <section id="CD002878-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed all identified abstracts; PJW and RSG for the 2002 version, FMS and PJW for the 2013 update, and TR and MD for the current update. When the review authors selected an abstract, we attempted to retrieve the full papers. The same two review authors read these in detail, and resolved any disagreements by consensus. </p> </section> <section id="CD002878-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>After inclusion of the studies, one author (TR) extracted the study characteristics of all included studies. We then contacted all trial authors by email to request the IPD of the following variables: treatment allocation, age, sex, body mass index, number of exacerbations and hospitalisations, arterial blood gases (PaO<sub>2</sub>, PaCO<sub>2</sub>, rate of oxygen flow), lung function (FEV<sub>1</sub>, FVC, FEV<sub>1</sub>/FVC), lung volumes (RV%/TLC), maximum static expiratory (PEmax) and inspiratory (PImax) mouth pressures, 6MWD, sleep studies, dyspnoea and HRQL measures (TDI, (modified) MRC dyspnoea scale, SRI, SGRQ), time‐to‐event and event status, NIV settings (inspiratory‐ and expiratory positive airway pressures (IPAP, EPAP)) and NIV compliance (mean hours of usage per night, as read from the ventilator counter). We requested missing data from the included primary studies from the authors. We checked supplied data against study publications, after which we copied raw data from all included studies to one main database. </p> <p>For the aggregated data, we calculated the mean of the absolute change between the baseline measurement and the value at the follow‐up visits (three and 12 months) of the identified outcome variables (± standard deviations (SD)) from the IPD. If the IPD were not available, two review authors (TR and MD) independently extracted the aggregated data from the studies' primary references. </p> </section> <section id="CD002878-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TR and MD) assessed the risk of bias of each study independently, including the seven studies of the 2013 review. We resolved disagreements by consensus. We used criteria for assessment of risk of bias as provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002878-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). We considered potential for bias using the following domains: </p> <p> <ul id="CD002878-list-0007"> <li> <p>random sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias), separately for:</p> <ul id="CD002878-list-0008"> <li> <p>participant‐reported outcomes (HRQL, dyspnoea),</p> </li> <li> <p>lung function, respiratory muscle testing, exercise tests,</p> </li> <li> <p>arterial blood gases, hospitalisations, mortality;</p> </li> </ul> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective outcome reporting (reporting bias);</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We judged each domain as 'high', 'low' or 'unclear' risk of bias. If a trial reported insufficient details, the judgment was 'unclear'. </p> </section> <section id="CD002878-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous data, we calculated and presented an absolute difference in the outcome between the baseline measurement and both follow‐up measurements (three and 12 months). Of these differences, we obtained an overall treatment effect that is presented as the adjusted mean difference (AMD) or standardised mean difference (SMD) for the pooled IPD analysis and as mean difference (MD) or SMD with associated 95% CI for the aggregated data meta‐analysis. We measured the number of COPD exacerbations and hospitalisations as continuous data. We dichotomised these data to participants who experienced none versus at least one exacerbation and obtained the odds ratio (OR). Lastly, we analysed survival data as time‐to‐event. The survival data obtained from the IPD are presented as adjusted hazard ratio (AHR) and as hazard ratio (HR) when obtained from the aggregated data meta‐analysis.  </p> <p>All outcome measures were presented with associated 95% confidence interval (CI). If available, estimates of the treatment effect were related to the minimal clinical important difference (MCID) for this specific population. Different proportions of participants and studies contributed to the different outcomes. </p> </section> <section id="CD002878-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We expressed study outcomes in the same natural units across the trials. We analysed arterial blood gases as kPa, and converted data provided as mmHg to kPa by dividing the mmHg value by 7.5. If we obtained data on capillary blood gases, we only used the data for the PaCO<sub>2</sub> analysis, as the PaO<sub>2</sub> cannot be obtained reliably from capillary blood gases (<a href="./references#CD002878-bbs2-0055" title="MagnetFS , MajorskiDS , CallegariJ , SchwarzSB , SchmoorC , WindischW , et al. Capillary PO2 does not adequately reflect arterial PO2 in hypoxemic COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2017;6(12):2647-53. [DOI: 10.2147/COPD.S140843]">Magnet 2017</a>). We analysed lung function parameters in absolute values (litres). If we could only collect the percentage of predicted values, we calculated the absolute values using the regression equations of the European Community for Steel and Coal reference values (<a href="./references#CD002878-bbs2-0060" title="Quanjer PhH, TammelingGJ , CotesJE , PedersenOF , PeslinR , Yernault J-C. Lung volumes and forced ventilatory flows. European Respiratory Journal 1993/03/01;6(Suppl 16):5.">Quanjer 1993</a>). We standardised the IPD of the SRI and SGRQ. Since the direction of effect differs between the SGRQ and the SRI, we inverted the SGRQ scores after which the data were pooled the data with the SRI. If a study measured both questionnaires, we preferred the data of the SRI over the SGRQ as the SRI was designed and validated specifically for this population (<a href="./references#CD002878-bbs2-0075" title="WindischW , FreidelK , SchucherB , BaumannH , WiebelM , MatthysH , et al. The Severe Respiratory Insufficiency (SRI) Questionnaire: a specific measure of health-related quality of life in patients receiving home mechanical ventilation. Journal of Clinical Epidemiology2003;56:752-9. [DOI: 10.1016/s0895-4356(03)00088-x]">Windisch 2003</a>; <a href="./references#CD002878-bbs2-0076" title="WindischW , BudweiserS , HeinemannF , PfeiferM , RzehakP . The Severe Respiratory Insufficiency Questionnaire was valid for COPD patients with severe chronic respiratory failure. Journal of Clinical Epidemiology2008;61(8):848-53.">Windisch 2008</a>). We could not pool the data on the dyspnoea measurements (TDI and the MRC dyspnoea scale), as the data of the MRC dyspnoea scale were not normally distributed. </p> <p>In the case of cross‐over studies, we considered only the first study period (prior to the cross‐over). In case of multi‐arm studies, we only considered the control arm (receiving only standard treatment) and the arm receiving NIV in addition to standard treatment. We did not consider cluster‐randomised trials to be relevant to this review. </p> </section> <section id="CD002878-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the trial authors to obtain the IPD for the included studies. We only used data on continuous variables if both baseline data and data from at least one follow‐up visit were available. For the exacerbation and hospitalisation data, we did not use baseline data. For this outcome, we only used the data of the participants that completed the follow‐up visit. For time‐to‐event data, we used all available data. </p> <p>If the authors did not respond to our request, we only used the studies for the meta‐analysis of the aggregated trial data and not for the pooled IPD analysis. </p> </section> <section id="CD002878-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity between the studies in each meta‐analysis using the Chi² test and I<sup>2</sup> statistic. For the Chi<sup>2</sup> test, we considered a P value of &lt; 0.1 significant. The I<sup>2</sup> statistic ranges from 0 to 100%, with 0% representing no heterogeneity and 100% representing considerable heterogeneity. We categorised the I<sup>2</sup> statistics according to the recommendations in the <i>Cochrane Handbook</i> (<a href="./references#CD002878-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>): </p> <p> <ul id="CD002878-list-0009"> <li> <p>0% to 40%: heterogeneity might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: shows considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD002878-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We created and inspected a funnel plot of the meta‐analysis of the primary outcomes where we were able to meta‐analyse 10 or more studies for an outcome, and if the results of the outcome were homogeneous between studies.  </p> </section> <section id="CD002878-sec-0035"> <h4 class="title">Data synthesis</h4> <p>For the analysis of the IPD, we used a one‐stage approach. We conducted all our models with a random effect on study level to account for the clustering of participants within the studies. We analysed the continuous IPD using linear mixed‐effect models to obtain the AMD. We analysed age, sex and treatment (NIV versus controls) as fixed factors. Normality of the outcome distributions was required, and we assessed this by visual inspection of normal probability plots and histograms. We used generalised estimating equations to obtain the OR from dichotomous IPD, with age, sex and treatment (NIV versus controls) as fixed factors. We ran separate models for both follow‐up times (3 and 12 months). </p> <p>We assessed time‐to‐event data using a mixed‐effect Cox regression analysis to obtain the AHR.  For the cohort of people with stable COPD, we entered age, sex, baseline PaCO<sub>2</sub> and treatment (NIV versus controls) as fixed factors. For the post‐exacerbation cohort, we entered age, sex, number of hospital admissions (less than three versus three or more admissions) in the year prior to randomisation, baseline PaCO<sub>2</sub> and treatment (NIV versus controls). We conducted all analyses in <a href="./references#CD002878-bbs2-0066" title="RStudio: Integrated Development Environment for R.. RStudio Team . Boston, MA: RStudio, PBC, 2020.">RStudio 2020</a>. </p> <p>Additionally, conducted a meta‐analysis on the (unadjusted) aggregated data of all included studies using Review Manager Web (<a href="./references#CD002878-bbs2-0062" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). In addition to the aggregated IPD, we included the extracted data from the studies that did not provide any IPD. We calculated the mean differences (MD) and associated 95% CI, and combined them in a random‐effects model to obtain an overall effect estimate. </p> </section> <section id="CD002878-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified any substantial heterogeneity between the studies (I<sup>2</sup> &gt; 50%), we considered subgroup analyses if sufficient numbers of studies could be included in the analysis (≥ 10 studies). A priori, the following sources of heterogeneity were postulated. </p> <p> <ul id="CD002878-list-0010"> <li> <p>Participants with more severe hypercapnia (PaCO<sub>2</sub> &gt; 7.3 kPa) might benefit more from NIV; the division of the subgroups was made based on guidelines from a consensus report (<a href="./references#CD002878-bbs2-0041" title="No authors listed. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. Chest1999;116(2):521-34. [DOI: 10.1378/chest.116.2.521]">Chest 1999</a>). </p> </li> <li> <p>Participants receiving higher ventilatory support (IPAP ≥ 18 cmH<sub>2</sub>O) might have a greater benefit from NIV; the division of the subgroups was made based on the first trial that showed an effect of NIV on gas exchange (<a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>). </p> </li> <li> <p>The benefits of NIV might be greater among participants who actually adhere to the NIV for at least five hours per night; division of the subgroups was made based on the inclusion criteria for this review that the NIV should be prescribed for at least five hours per night. </p> </li> </ul> </p> </section> <section id="CD002878-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses based on methodological quality by repeating the IPD analysis among only those studies that we judged to be of 'high quality.' Studies defined as 'high‐quality' studies were studies that we judged to be at low risk of bias for the following domains: random sequence generation, allocation concealment, incomplete outcome data. We limited the sensitivity analysis to the primary outcomes. </p> </section> <section id="CD002878-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created the summary of findings tables using <a href="./references#CD002878-bbs2-0050" title="GRADEpro GDT. Version accessed 1 July 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available from gradepro.org.">GRADEpro GDT</a> software, and presented separate tables for participants with stable COPD and for post‐exacerbation COPD. We included the primary outcomes and the (admission‐free) survival outcomes of the pooled IPD analysis in the tables. </p> <p>Two review authors (TR and MD) assessed the certainty of the evidence using the GRADE working group criteria (<a href="./references#CD002878-bbs2-0049" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group, October 2013.">GRADE 2013</a>), considering the following domains: risk of bias, inconsistency, indirectness, imprecision, publication bias. We described our decisions to downgrade the certainty of the evidence. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002878-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002878-sec-0039"></div> <section id="CD002878-sec-0040"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD002878-sec-0146" title="">Characteristics of included studies</a>. </p> <section id="CD002878-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search conducted on 21 December 2020 identified 2291 records. After deduplication 1709 records remained, of which we considered 1653 records ineligible after title and abstract screening. Of the 56 records that remained, we retrieved 22 full‐text papers. The remaining records were conference abstracts (n = 27) or records from trial registries (n = 7). Of the 56 records, we excluded nine records of the current search for the following reasons. </p> <p>1) Ineligible study design:</p> <p> <ul id="CD002878-list-0011"> <li> <p>study not randomised (<a href="./references#CD002878-bbs2-0022" title="Ali MS , TalwarD , SinghM . Nocturnal noninvasive ventilation improves muscle strength in stable COPD patients with respiratory failure DBP - EM:201332. Thorax2013;67(Suppl 2):A165 (P229). ">Ali 2012</a>; <a href="./references#CD002878-bbs2-0024" title="CliniE , StruraniC , PortaR . Outcome of COPD patients performing nocturnal non-invasive mechanical ventilation. Respiratory Medicine1998;92:1215-22. ">Clini 1998</a>; <a href="./references#CD002878-bbs2-0027" title="KameiM . Effectiveness of noninvasive positive-pressure ventilation for patients with chronic stable hypercapnic respiratory failure. Nihon Koyuki Gakkai Zasshi1999;37(11):886-92. ">Kamei 1999</a>); </p> </li> <li> <p>duration of NIV was less than four hours per night prescribed use and prescribed at daytime (<a href="./references#CD002878-bbs2-0025" title="DiazO , GallardoJ , RamosJ , TorrealbaB , LisboaC . Non-invasive mechanical ventilation in severe stable hypercapnic COPD patients: a prospective randomised clinical trial. American Journal of Respiratory and Critical Care Medicine1999;159:A295. ">Diaz 1999</a>); </p> </li> <li> <p>use of NIV was less than three weeks (<a href="./references#CD002878-bbs2-0028" title="LinCC . Comparison between nocturnal nasal positive pressure ventilation combined with oxygen therapy and oxygen monotherapy in patients with severe COPD. American Journal of Respiratory and Critical Care Medicine1996;154:353-8. LinCC . Effect of nocturnal nasal positive pressure ventilation plus oxygen combined therapy and oxygen monotherapy in severe COPD patients. European Respiratory Journal1995;8(Suppl 19):210S. ">Lin 1996</a>); </p> </li> <li> <p>participants were randomised to either terminate or continue NIV after an exacerbation (<a href="./references#CD002878-bbs2-0026" title="Funk G-C,  Breyer M-K,  BurghuberOC , KinkE , KirchheinerK , KohansalR , et al. Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure. Respiratory Medicine2011;105(3):427-34. [DOI: 10.1016/j.rmed.2010.09.005]">Funk 2011</a>). </p> </li> </ul> </p> <p>2) Ineligible study population:</p> <p> <ul id="CD002878-list-0012"> <li> <p>mixed population of participants with obstructive lung diseases (<a href="./references#CD002878-bbs2-0023" title="ChiangLL , LiuCY , HoSC , ShengTF , YuCT , LinHC , et al. Efficacy of nocturnal nasal positive pressure ventilation in hypercapnic patients with severe obstructive lung diseases. Chang Gung Medical Journal2004;27(2):98-106. ChiangLL , YuCT , LiuCY , LoYL , KuoHP , LinHC . Six-month nocturnal nasal positive pressure ventilation improves respiratory muscle capacity and exercise endurance in patients with chronic hypercapnic respiratory failure. Journal of the Formosan Medical Association/Taiwan2006;105(6):459-67. ">Chiang 2004</a>, two records). </p> </li> </ul> </p> <p>3) Ineligible intervention:</p> <p> <ul id="CD002878-list-0013"> <li> <p>intervention group received inspiratory positive pressure breathing during daytime (<a href="./references#CD002878-bbs2-0029" title="NicoliniA , MollarE , GrecchiB , LanducciN . Comparison of Intermittent positive pressure breathing and temporary positive expiratory pressure in patients with severe chronic obstructive pulmonary disease. Archivos de bronconeumologia2017;50:18-24. [DOI: 10.1016/j.arbres.2013.07.019]">Nicolini 2014</a>). </p> </li> </ul> </p> <p>Three studies (one full text paper and two conference abstracts) are awaiting classification as the authors did not respond to clarify important issues (<a href="./references#CD002878-bbs2-0030" title="BaturovaV , ZolotovaE , SvetA , NesterovA , K Dalgatova. Effectiveness of non-invasive ventilation in stable chronic obstructive pulmonary disease with nocturnal desaturation: Prospective open-label randomized parallel-group study. In: European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona. 2013. ">Baturova 2013</a>; <a href="./references#CD002878-bbs2-0031" title="GuanL , ZhouL , ChenR . Home noninvasive ventilation with built-in software in chronic hypercapnic COPD patients: a mid-term prospective, multicenter, randomized, controlled trial. European Respiratory Journal2018;52((suppl 62)):PA1677. [DOI: 10.1183/13993003.congress-2018.PA1677]">Guan 2018</a>; <a href="./references#CD002878-bbs2-0032" title="XiangPC , ZiangPC , ZhangX , YangJN , ZhangEM , GouWA , et al. The efficacy and safety of long term home noninvasive positive pressure ventilation in patients with stable severe chronic obstructive pulmonary disease. Chinese Journal of Tuberculosis and Respiratory Diseases2007;30(10):746-50. ">Xiang 2007</a>). We identified six studies (seven records) that were ongoing at the time of this review (<a href="./references#CD002878-bbs2-0033" title="AnkjaergaardKL , TonnesenP , LaursenLC , HansenEF , AndreassenHF , WilckeJT . Home non invasive ventilation (NIV) treatment for COPD patients with a history of NIV-treated exacerbation; a randomized, controlled, multi-center study DBP - 201721. BMC Pulmonary Medicine2016;16(1):32. ">Ankjaergaard</a>; <a href="./references#CD002878-bbs2-0034" title="NCT04210050. Sleep ventilation for patients with advanced hypercapnic COPD [Implementation of a precision sleep ventilation (PSV) chronic respiratory failure management program for patients with advanced hypercapnic COPD]. clinicaltrials.gov/ct2/show/NCT04210050 (first received 24 December 2019). ">Beth Israel Deaconess Medical Center</a>; <a href="./references#CD002878-bbs2-0035" title="NCT03890224. Respiratory support in chronic obstructive pulmonary disease (COPD) patients [Respiratory support in chronic obstructive pulmonary disease (COPD) patients after acute exacerbation with monitoring the quality of support]. clinicaltrials.gov/ct2/show/NCT03890224 (first received 26 March 2019). ">Gonzales</a>; <a href="./references#CD002878-bbs2-0036" title="LamiaB , CuvelierA , BenichouJ , MuirJF . A multi-centre randomized controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study.. Revue des maladies respiratoires2012;29(9):1141-8. NCT03221101. Home non invasive ventilation for COPD patients (NIVOLD) [Home non invasive ventilation versus long term oxygen therapy alone in COPD survivors after acute hypercapnic respiratory failure. A French multicenter randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03221101 (first received 18 July 2017). ">Lamia</a>; <a href="./references#CD002878-bbs2-0037" title="NCT03584269. Innovation in NOn invasive ventilation in COPD patients treated by long term oxygen therapy (INOV-LTOT) [Non invasive ventilation and nocturnal alveolar hypoventilation in patients with chronic obstructive pulmonary disease (COPD) treated by long term oxygen therapy at home]. clinicaltrials.gov/show/nct03584269 (first received 12 July 2018). ">Pepin</a>; <a href="./references#CD002878-bbs2-0038" title="NCT03053973. The effects of nocturnal non-invasive ventilation in stable COPD (RECAPTURE) [Nocturnal non-invasive ventilation in COPD patients with stable hypercapnic respiratory failure: why and in which patient might this be effective?]. clinicaltrials.gov/show/nct03053973 (first received 15 February 2017). ">Wijkstra</a>). Additionally, we identified five records of studies that were included in the previous version of this review. </p> <p>This update identified 10 studies (18 records) investigating chronic NIV in stable COPD (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). Together with the seven studies from the original review, we included 17 studies on stable COPD in this review update. Additionally, we identified four studies (14 records) on chronic NIV following an acute exacerbation of COPD (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). In total, we included 21 studies in this review update.  </p> <p><a href="#CD002878-fig-0001">Figure 1</a> presents the PRISMA‐IPD flowchart.  </p> <div class="figure" id="CD002878-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD002878-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD002878-sec-0042"> <h4 class="title">Included studies</h4> <p>The <a href="./references#CD002878-sec-0146" title="">Characteristics of included studies</a> table shows full details of the included studies. </p> <section id="CD002878-sec-0043"> <h5 class="title">Stable COPD</h5> <p>Seventeen studies met the inclusion criteria for the review (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). Two of these studies used a cross‐over in design (<a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>), the remaining studies adopted a parallel design. Fourteen studies measured outcomes after three months and are classified as 'short‐term', while five studies also measured outcomes after 12 months and are defined as 'long‐term' (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). We obtained the IPD for the studies from the trial authors, except for four studies (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>). Of these four studies, we could only include the aggregated data of <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a> for the meta‐analysis. In one study, the treatment arm received either NIV or CPAP, and the trial did not report the number of participants receiving each treatment (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>). One study only measured the outcomes after six months of NIV, so we did not use the data (<a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>). In the other trial, the study report did not present the data (<a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>). </p> <section id="CD002878-sec-0044"> <h6 class="title">Participants</h6> <p>The 17 included studies were based in different countries: Australia (<a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>), Canada (<a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>), China (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), Egypt (<a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>), Germany (<a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>), the Netherlands (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>), Spain (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>), Italy (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>), the UK (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>) and the USA (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). All studies included people with COPD in a clinically stable condition and included both males and females. </p> <p>In total, we obtained the IPD of 778 participants with stable COPD, representing 68% of the participants included in the studies. The mean age of all participants was 66 ± 8 years. All studies included males and females; 71% were males. Mean FEV<sub>1 </sub>was 0.72 ± 0.27 L (28.2% predicted) and mean PaCO<sub>2</sub> was 7.3 ± 1.1 kPa. </p> </section> <section id="CD002878-sec-0045"> <h6 class="title">Intervention and comparator</h6> <p>Eleven studies compared chronic NIV with standard treatment (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), and two studies compared chronic NIV with sham treatment in the form of continuous positive airway pressure (CPAP) at 2 cmH<sub>2</sub>O and 4 cmH<sub>2</sub>O (<a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). In four studies, NIV was applied in addition to a pulmonary rehabilitation or exercise training program and compared to a control group receiving only the rehabilitation or training program (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). </p> <p>Participants allocated to the NIV were initiated in‐hospital (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>), out‐patient based (<a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>) or at home (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>). The remaining three studies did not report the site of initiation (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>). Bi‐level pressure support ventilation was applied with a back‐up rate in eight studies (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), with no back‐up rate (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>), or information on a back‐up rate was not specified (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). The ventilation mode was unspecified in one study (<a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>). NIV was delivered by nasal masks in six studies (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>), and by either nasal or oronasal masks in seven studies (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). In four studies the interface was not specified (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). </p> <p>At baseline, the mean IPAP and EPAP were 16.5 ± 4.7 cmH<sub>2</sub>O and 4.7 ± 4.7 cmH<sub>2</sub>O, respectively. The corresponding values after three months were 17.9 ± 5.2 cmH<sub>2</sub>O and 4.6 ± 1.4 cmH<sub>2</sub>O, respectively. After 12 months, mean IPAP was 16.8 ± 5.4 cmH<sub>2</sub>O and mean EPAP was 4.9 ± 1.5 cmH<sub>2</sub>O. Chronic NIV was used for a mean of 6.2 ± 2.8 hours after three months and 5.5 ± 3.2 hours after 12 months. </p> </section> </section> <section id="CD002878-sec-0046"> <h5 class="title">Post‐exacerbation COPD</h5> <p>Four studies met the inclusion criteria for this review (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). All studies used a parallel design and measured outcomes after both three and 12 months. The authors of one study did not respond to our request for the IPD (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>), so we did not include this study in the pooled IPD analysis. Since <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a> did not present results in their paper after three or 12 months, we were also unable to use the data from this study in the meta‐analysis. The remaining three studies provided the IPD after both three and 12 months.  </p> <section id="CD002878-sec-0047"> <h6 class="title">Participants</h6> <p>The four included studies were based in the following countries: Belgium (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>), China (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>), the Netherlands (<a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>), and the UK (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>). The studies included people with COPD who were hospitalised due to an exacerbation (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>) or who were hospitalised for an episode of ARF due to COPD (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). All studies included both males and females. </p> <p>We obtained IPD for 364 participants initiated on chronic NIV following an acute exacerbation, representing 96% of the participants included in the studies. The mean age was 65 ± 9 years, and 50% were females. In the year prior to randomisation, the median number of COPD exacerbations was two (interquartile range (IQR) one to three). The mean FEV<sub>1</sub> was 0.62 ± 0.23 L and mean (inclusion) PaCO<sub>2</sub> was 7.9 ± 1.1 kPa.  </p> </section> <section id="CD002878-sec-0048"> <h6 class="title">Intervention and comparator</h6> <p>In one study (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>), chronic NIV was compared to sham treatment with CPAP at 5 cmH<sub>2</sub>0, the remaining three studies compared NIV to standard treatment. Participants were initiated on chronic NIV if they had persistent hypercapnia on day five to 12 of the admission (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>), or after they were weaned from acute NIV &gt; 48 hours (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>) or two to four weeks (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>). All participants were initiated in‐hospital, and on bi‐level pressure support ventilation with a backup rate in three studies (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). The other study did not report the mode of ventilation (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>). NIV was delivered through oronasal masks (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>), through either nasal or oronasal masks (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>), or was not specified (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>). </p> <p>The mean IPAP and EPAP at initiation were 20.0 ± 4.4 cmH<sub>2</sub>O and 4.8 ± 0.9 cmH<sub>2</sub>O, respectively. After three months, the mean IPAP was 20.8 ± 4.4 cmH<sub>2</sub>O and the mean EPAP was 5.0 ± 1.0 cmH<sub>2</sub>O. Mean IPAP after 12 months was 21.9 ± 4.3 cmH<sub>2</sub>O, and the corresponding mean EPAP was 5.0 ± 1.1 cmH<sub>2</sub>O. Chronic NIV was used for a mean of 6.5 ± 2.4 hours after three months and for 6.8 ± 2.7 hours after 12 months. </p> </section> </section> <section id="CD002878-sec-0049"> <h5 class="title">Funding of trial (all trials)</h5> <p>Thirteen studies were funded by their National Respiratory Society/Foundation (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), of which six were also partly funded by an industrial company (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). Four studies were funded by an industrial company alone (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>), and four studies did not report any funding (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>). </p> </section> </section> <section id="CD002878-sec-0050"> <h4 class="title">Excluded studies</h4> <p>The <a href="./references#CD002878-sec-0147" title="">Characteristics of excluded studies</a> table provides full details of the 10 excluded studies. </p> </section> </section> <section id="CD002878-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>The <a href="./references#CD002878-sec-0146" title="">Characteristics of included studies</a> table provides details of risk of bias in the included studies. <a href="#CD002878-fig-0002">Figure 2</a> shows a summary of our risk of bias judgements across studies.  </p> <div class="figure" id="CD002878-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each methodological quality item for each included studyNote: blank squares indicate that the outcome domain was not measured in the study." data-id="CD002878-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each methodological quality item for each included study </p> <p>Note: blank squares indicate that the outcome domain was not measured in the study.</p> </div> </div> </div> <section id="CD002878-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD002878-sec-0053"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>All studies were described as randomised. Thirteen studies described the method of the sequence generation adequately, so we judged these to be at low risk of bias. In the other eight studies, insufficient data were available, so we judged these to be at unclear risk of bias (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). </p> </section> <section id="CD002878-sec-0054"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We also deemed allocation concealment to be adequate in the majority of the studies; 10 studies described a centralised randomisation office or independent person. In six cases, sequentially numbered, opaque, sealed envelopes were used. Five studies provided insufficient data on the allocation concealment, so we judged them to be at unclear risk of bias in this domain (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>). </p> </section> </section> <section id="CD002878-sec-0055"> <h4 class="title">Blinding</h4> <section id="CD002878-sec-0056"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Given the nature of the intervention it is difficult to blind participants, but three studies attempted to do so and used a sham‐device (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). One study also blinded personnel to treatment allocation, making this the only study that we could classify as having a low risk of bias in this domain (<a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). In one other study it was not clear whether personnel were blinded (<a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>). We judged all other studies to be at high risk of bias with respect to blinding. </p> </section> <section id="CD002878-sec-0057"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <section id="CD002878-sec-0058"> <h6 class="title">Participant‐reported outcomes</h6> <p>In the majority of the studies, participants were not blinded for treatment (e.g. did not receive sham NIV), so we judged that participant‐reported outcomes (HRQL and dyspnoea measurements) were likely to be affected by detection bias. Therefore, we judged 15 studies to be at high risk of bias. The remaining studies did not measure any participant‐reported outcomes of relevance to this review (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). </p> </section> <section id="CD002878-sec-0059"> <h6 class="title">Lung function, respiratory muscle and exercise capacity tests</h6> <p>Most studies did not provide sufficient data on these outcomes, so we judged them to be at unclear risk. Eight studies described the outcome assessors as being unaware of the treatment assignment, so we judged these to be at low risk (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). The <a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a> study did not measure these outcomes. </p> </section> <section id="CD002878-sec-0060"> <h6 class="title">Arterial blood gases, hospitalizations and mortality</h6> <p>Except for one study, we judged all studies to be at low risk of bias as these are either objective measures (e.g. blood gases) or are unlikely to be affected by the outcome assessor (e.g. hospitalisations/mortality). We judged the study of <a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a> as high risk as for the primary outcome, as outcome assessors had to rate whether there was an event in the NIV group. One study did not measure these outcomes (<a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). </p> </section> </section> </section> <section id="CD002878-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Given the severity of the illness and nature of the intervention, dropouts are to be expected due to the inability of the participants to attend control visits, or because of intolerance to the intervention. Therefore, most studies experienced dropouts, and the majority described the reason for these dropouts adequately. Five studies did not perform intention‐to‐treat (ITT) analyses. We classified these studies as low risk as dropouts due to intolerance were small, baseline characteristics of dropouts did not differ from completers, and the studies presented a clear description of the reason for participants dropping out (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>). Eight studies reported ITT analyses (or stated that “Inclusion of the patients who did not complete the study (intent to treat) did not affect any of the outcomes” <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>), so we considered these to be at low risk of bias (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). In one of the cross‐over studies, only seven out of 19 randomised participants completed both arms (<a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). Another study reported that four out of seven participants randomised to NIV completed the study, as opposed to all six in the sham group (<a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>). One study performed an ITT analysis on the primary outcome, but participants were withdrawn from the study after the primary outcome was reached (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>). We classified these three studies as high risk of attrition bias. We judged five studies to be at unclear risk of bias, as these studies did not provide sufficient data regarding the reasons for participants dropping out (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). </p> </section> <section id="CD002878-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Most of the earlier studies were not registered, nor were the original protocols retrieved, so we were unable to check if the prespecified outcomes were all reported in the articles. In this domain the risk of bias was unclear. However, all outcomes listed in the methods sections of the studies were reported in the results sections. One study was registered retrospectively, and we judged this as unclear (<a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). One study was not registered and the paper only reported the outcome data of one follow‐up visit, whilst measurements were taken during four follow‐up visits (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>). We therefore judged this study to be at high risk. We judged two other studies to be high risk after comparing the paper with the trial registry, due to a change in the primary outcome (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). We judged eight studies to be at low risk, as these studies were registered and the data were reported in the paper, or (in case that the data were not reported), the authors provided the IPD (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). </p> </section> <section id="CD002878-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>For 13 of the studies, we did not find any other source of bias. In one study we found a difference in the number of (telephone) contacts with the caregivers between both study groups at the start of the study, but as it was unclear for how long this activity continued (and thus the likelihood of affecting the outcomes after three months), we judged this as an unclear risk of bias (<a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). We also observed this in two other studies (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>), and the NIV group in one of these studies received NIV during the run‐in period, which could potentially affect the outcomes (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>). In two studies, there were concerns regarding the sample size; in one study financial restraint prevented the inclusion of more than 50 participants, and one study did not present a power calculation and the sample sizes of both groups were unequal (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>). In one study, participants with both hypoxemic and hypercapnic respiratory failure were included and treated with either CPAP or NIV in the treatment arm (<a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>). The study did not provide data on the number of participants treated with either treatment, so we judged this study to have a high risk of bias. Lastly, two studies were only available as meeting abstracts (<a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). Therefore, we judged all seven of these studies to be at high risk of other bias (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0005" title="LiminC , HaixiaL , LeiS . Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease.. Pakistan Journal of Medical Science2019;35(2):500-5. [DOI: 10.12669/pjms.35.2.459]">Cui 2019</a>; <a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0012" title="MaT , HuY , YanB . The analysis of non-invasive positive pressure ventilation in treating COPD patients accompanied with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine2019;199(B44):A3344. [DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3344]">Ma 2019</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). </p> </section> </section> <section id="CD002878-sec-0064"> <h3 class="title" id="CD002878-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD002878-tbl-0001"><b>Summary of findings 1</b> Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</a>; <a href="./full#CD002878-tbl-0002"><b>Summary of findings 2</b> Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</a> </p> <p>There is a difference between the number of participants included in the studies in total and the number included in the analysis, as most of the data were only available from participants who completed that particular study period and dropouts were common in most studies. For the short‐term follow‐up, participants dropped out due to mask intolerance, intercurrent infections or participants no longer meeting the inclusion criteria after a stabilisation period. In the studies also investigating the long‐term effects, dropping out was often due to progression of the disease or death, and reluctance of participants to return to hospital for follow‐up measurements. Finally, not all parameters were measured in all participants and, therefore, there was a difference in number of participants per outcome. </p> <section id="CD002878-sec-0065"> <h4 class="title">Stable COPD — primary outcomes</h4> <p>In <a href="#CD002878-tbl-0003">Table 1</a>, the absolute changes in the outcomes are shown separately for the NIV and the control group. In <a href="#CD002878-fig-0003">Figure 3</a>, the modelled means obtained from the linear mixed effect models are presented for the primary outcomes.  </p> <div class="table" id="CD002878-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in stable COPD, separate for the NIV and the control group</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>3 months</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>12 months</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaO<sub>2</sub> </b> (kPa) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17 ± 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 ± 0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 ± 1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.06 ± 1.12</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaCO<sub>2</sub> </b> (kPa) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.81 ± 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 ± 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.46 ± 1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 0.98</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6MWD</b> (m) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2 ± 73.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 75.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 105.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.7 ± 94.8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SRI,</b> summary score </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 ± 14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 ± 9.3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SGRQ,</b> total score </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.2 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 ± 8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 ± 14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.9 ± 15.3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> </b> (l) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 ± 0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 ± 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 ± 0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 ± 0.15</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FVC </b>(l) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 ± 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 ± 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 ± 0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 0.46</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RV/TLC</b> (%) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.6 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 ± 8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 ± 9.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PEmax </b>(cmH<sub>2</sub>O) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7 ± 24.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 ± 23.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 36.1</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PImax</b> (cmH<sub>2</sub>O) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 16.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 ± 16.5</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>TDI</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>(m)MRC</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.7 ± 1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.4 ± 0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.6 ± 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.1 ± 1.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sleep efficiency</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 ± 16.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>COPD exacerbations</b><sup>a</sup> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0 to 1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0 to 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.8 to 4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.0 to 5.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>COPD hospitalisations</b><sup>a</sup> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 2.0)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data are based on the studies that provided the IPD, and are presented as mean ± standard deviation or median (interquartile range). <br/><sup>a</sup> absolute number of exacerbations or hospitalisations. </p> <p>6MWD: 6‐minute walking distance; CI: confidence interval; COPD: Chronic Obstructive Pulmonary Disease; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; (m)MRC: (modified) Medical Research Council dyspnoea scale, a decrease indicates an improvement in dyspnoea; NIV: noninvasive ventilation; PaCO<sub>2</sub>: arterial carbon dioxide tension; PaO<sub>2</sub>: arterial oxygen tension; PEmax: peak expiratory pressure; PImax: peak inspiratory pressure; RV/TLC: residual volume/total lung capacity; SGRQ: St. George's Respiratory Questionnaire, a decrease indicates an improved health‐related quality of life; SRI: Severe Respiratory Insufficiency questionnaire, an increase indicates an improved health‐related quality of life; TDI: transitional dyspnoea index, a positive value indicates an improvement in dyspnoea. </p> </div> </div> <div class="figure" id="CD002878-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in stable COPDBlack triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL." data-id="CD002878-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in stable COPD </p> <p>Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL. </p> </div> </div> </div> <section id="CD002878-sec-0066"> <h5 class="title">Daytime arterial blood gas tensions</h5> <section id="CD002878-sec-0067"> <h6 class="title">Three months' follow‐up</h6> <p>Eleven studies contributed IPD for this outcome (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). In total, blood gases of 475 participants were analysed, of which 271 were arterial blood gases and contributed to the PaO<sub>2</sub> outcome. Participants treated with NIV showed an increase in PaO<sub>2</sub> whereas participants allocated to the control group showed a decrease (adjusted mean difference (AMD) 0.27 kPa, 95% CI 0.04 to 0.49; <a href="#CD002878-tbl-0003">Table 1</a>). A reduction in the PaCO<sub>2</sub> was observed in participants in both groups, but the decrease was ‐0.61 kPa larger in participants allocated to NIV (95% CI ‐0.77 to ‐0.45; <a href="#CD002878-tbl-0003">Table 1</a>). </p> <p>The meta‐analyses of the blood gas outcomes included data from one additional study (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>), and showed a larger treatment effect on the PaO<sub>2</sub> (MD 0.31 kPa, 95% CI 0.14 to 0.48; P = 0.44, I<sup>2</sup> = 0%; 10 studies, 308 participants; moderate‐certainty evidence; <a href="./references#CD002878-fig-0008" title="">Analysis 1.1</a>). The funnel plot was asymmetrical to the right side and might indicate that a publication bias was present (<a href="#CD002878-fig-0004">Figure 4</a>). A smaller treatment effect with substantial statistical heterogeneity between the studies was found for the PaCO<sub>2</sub> (MD ‐0.48 kPa, 95% CI ‐0.72 to ‐0.25; P = 0.001, I<sup>2</sup> = 65%; 12 studies, 512 participants; high‐certainty evidence; <a href="./references#CD002878-fig-0009" title="">Analysis 1.2</a>). We conducted subgroup analysis to explore the heterogeneity. These subgroup analyses seem to explain the heterogeneity and are presented later. </p> <div class="figure" id="CD002878-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for the PaO2 outcome after 3 months, in participants with stable COPD" data-id="CD002878-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for the PaO<sub>2</sub> outcome after 3 months, in participants with stable COPD </p> </div> </div> </div> </section> <section id="CD002878-sec-0068"> <h6 class="title">12 months' follow‐up</h6> <p>Four studies contributed blood gases of 232 participants (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). Of these blood gases, 171 were arterial and were used for the PaO<sub>2</sub> analysis. Both study groups showed a minor decrease in PaO<sub>2</sub> (AMD 0.09 kPa, 95% CI ‐0.23 to 0.42; <a href="#CD002878-tbl-0003">Table 1</a>). In contrast, a reduction in PaCO<sub>2</sub> was only present in participants allocated to NIV, whereas participants in the control group did not change (AMD ‐0.42 kPa, 95% CI ‐0.68 to ‐0.16; <a href="#CD002878-tbl-0003">Table 1</a>). </p> <p>The meta‐analyses did not include additional data and yielded results comparable to the pooled IPD analysis for the PaO<sub>2</sub> (MD 0.08 kPa, 95% CI ‐0.37 to 0.53; P = 0.16, I<sup>2</sup> = 46%; 3 studies, 171 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0008" title="">Analysis 1.1</a>) and a slightly smaller effect of NIV on the PaCO<sub>2</sub> (MD ‐0.35 kPa, 95% CI ‐0.68 to ‐0.02; P = 0.14, I<sup>2</sup> = 45%; 4 studies, 232 participants; high‐certainty evidence; <a href="./references#CD002878-fig-0009" title="">Analysis 1.2</a>). Both outcomes showed moderate statistical heterogeneity between the studies, but as only four studies measured this outcome we could not conduct subgroup analysis. </p> </section> </section> <section id="CD002878-sec-0069"> <h5 class="title">Exercise capacity</h5> <section id="CD002878-sec-0070"> <h6 class="title">Three months' follow‐up</h6> <p>Exercise capacity was measured using the 6MWD in eight studies (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), and 330 participants contributed to the IPD. The MCID for the 6MWD in people with severe COPD is 26 m (<a href="./references#CD002878-bbs2-0059" title="PuhanMA , ChandraD , MosenifarZ , RiesA , MakeB , HanselNN , et al. The minimal important difference of exercise tests in severe COPD. European Respiratory Journal2011;37 Suppl:748-90. [DOI: 10.1183/09031936.00063810]">Puhan 2011</a>). Participants in both groups improved on the 6MWD on average, but there was no relevant effect of the NIV (AMD 15.5 m, 95% CI ‐0.8 to 31.7; <a href="#CD002878-tbl-0003">Table 1</a>). The meta‐analysis did not include additional data and yielded a smaller effect compared to the pooled IPD analysis (MD 7.85 m, 95% CI ‐5.52 to 21.23; P = 0.39, I<sup>2</sup> = 6%; 8 studies, 330 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0010" title="">Analysis 1.3</a>). </p> </section> <section id="CD002878-sec-0071"> <h6 class="title">12 months' follow‐up</h6> <p>The 6MWD was measured in 134 participants in three studies (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>). An improvement in the 6MWD was seen in the NIV group, whereas the control group deteriorated (AMD 26.4 m, 95% CI ‐7.6 to 60.5; <a href="#CD002878-tbl-0003">Table 1</a>). The meta‐analysis of data of the same three studies that provided IPD yielded similar results (MD 23.50 m, 95% CI ‐3.03 to 50.03; P = 0.37, I<sup>2</sup> = 0%; 3 studies, 134 participants; very low‐certainty evidence; <a href="./references#CD002878-fig-0010" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD002878-sec-0072"> <h5 class="title">Health‐related quality of life</h5> <section id="CD002878-sec-0073"> <h6 class="title">Three months' follow‐up</h6> <p>Three studies measured HRQL using the SRI in 217 participants (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). The SRI is reported on a 0 to 100 scale, with a higher score indicating better HRQL. An improvement of approximately five units has been established as the MCID (<a href="./references#CD002878-bbs2-0061" title="RavelingT , KortJ , BladderG , WindischW , WijkstraPJ , DuivermanML . The minimal clinically important difference of the Severe Respiratory Insufficiency questionnaire in severe COPD. European Respiratory Journal2020;56:2001334. [DOI: 10.1183/13993003.01334-2020]">Raveling 2020</a>). Three studies provided SGRQ data for an additional 42 participants (<a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>). Scores for the SGRQ are also reported on a 0 to 100 scale, but with a lower score indicating better HRQL. The MCID of the SGRQ in people with severe COPD is approximately seven units (<a href="./references#CD002878-bbs2-0072" title="Welling JB , HartmanJE , Ten HackenNH , KloosterK , SlebosDJ . The minimal important difference for the St George's Respiratory Questionnaire in patients with severe COPD. European Respiratory Journal2015;46(6):1598-604.">Welling 2015</a>). Participants treated with NIV showed a larger improvement both on the summary score of the SRI and on the total score of the SGRQ, compared to participants allocated to the control group (<a href="#CD002878-tbl-0003">Table 1</a>). After pooling of the SRI and SGRQ data, there was a benefit of NIV on HRQL (AMD 0.39, 95% CI 0.15 to 0.62). Given a SD of 12.0 and of 10.2 units for the SRI and SGRQ respectively, this would result in an improvement of 4.7 units on the SRI and of 4.0 units on the SGRQ. </p> <p>Meta‐analyses based on data of the same five studies that provided IPD yielded comparable results to the pooled IPD analysis (SMD 0.42, 95% CI 0.17 to 0.67; P = 0.43, I<sup>2</sup> = 0%; 5 studies, 257 participants; very low‐certainty evidence; <a href="./references#CD002878-fig-0011" title="">Analysis 1.4</a>). </p> </section> <section id="CD002878-sec-0074"> <h6 class="title">12 months' follow‐up</h6> <p>Two studies contributed to the SRI data of 84 participants (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>), and three studies to the SGRQ data of 116 participants (<a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). An improvement on the summary score of the SRI was observed in participants treated with NIV, but participants allocated to the control group showed no change. This was not observed in the studies that used the SGRQ, as both groups showed a small improvement (<a href="#CD002878-tbl-0003">Table 1</a>). After pooling of the SRI and SGRQ data, there was no effect of chronic NIV (AMD 0.15, 95% CI ‐0.13 to 0.43). Given a SD of 12.2 and of 14.6 units for the SRI and SGRQ respectively, this would result in an improvement of 1.8 units on the SRI and of 2.2 units on the SGRQ. </p> <p>There were no additional data available for the aggregated meta‐analyses, and this analysis yielded comparable results to the pooled IPD analysis (SMD 0.18, 95% CI ‐0.24 to 0.59; P = 0.12, I<sup>2</sup> = 49%; 4 studies; 199 participants; very low‐certainty evidence; <a href="./references#CD002878-fig-0011" title="">Analysis 1.4</a>). </p> </section> </section> </section> <section id="CD002878-sec-0075"> <h4 class="title">Stable COPD — secondary outcomes</h4> <section id="CD002878-sec-0076"> <h5 class="title">Lung function</h5> <p>In one study (<a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>), only the percentage of predicted values were recorded. Absolute spirometry values were calculated using regression equations (<a href="./references#CD002878-bbs2-0060" title="Quanjer PhH, TammelingGJ , CotesJE , PedersenOF , PeslinR , Yernault J-C. Lung volumes and forced ventilatory flows. European Respiratory Journal 1993/03/01;6(Suppl 16):5.">Quanjer 1993</a>). </p> <section id="CD002878-sec-0077"> <h6 class="title">Three months' follow‐up</h6> <p>The FEV<sub>1</sub> and FVC were measured in 10 studies (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). Data were available for 383 participants for the FEV<sub>1</sub> and of 384 participants for the FVC. On average, the FEV<sub>1</sub> of participants in both groups remained unchanged (AMD 0.01 L, 95% CI ‐0.02 to 0.04; <a href="#CD002878-tbl-0003">Table 1</a>). Similar results were observed for the FVC as participants in both groups showed a small but equal increase (AMD ‐0.01 L, 95% CI ‐0.09 to 0.07; <a href="#CD002878-tbl-0003">Table 1</a>). Aggregated data were available for one additional study (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>), but this did not result in any new findings for either the FEV<sub>1</sub> (MD ‐0.00 L, 95% CI ‐0.04 to 0.03; P = 0.18, I<sup>2</sup> = 28%; 11 studies, 420 participants; <a href="./references#CD002878-fig-0012" title="">Analysis 1.5</a>) or the FVC (MD 0.01 L, 95% CI ‐0.06 to 0.08; P = 0.80, I<sup>2</sup> = 0%; 11 studies, 421 participants; <a href="./references#CD002878-fig-0013" title="">Analysis 1.6</a>). </p> <p>Lung hyperinflation (RV/%TLC) was measured in three studies (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>), and 184 participants contributed to the IPD. There were only minor changes in RV/%TLC of participants in both study groups (AMD ‐0.6 %, 95% CI ‐2.6 to 1.4; <a href="#CD002878-tbl-0003">Table 1</a>). The meta‐analysis of the RV/%TLC data yielded similar results to the pooled IPD analysis (MD ‐0.53%, 95% CI ‐2.77 to 1.71; P = 0.30, I<sup>2</sup> = 17%; 3 studies, 184 participants; <a href="./references#CD002878-fig-0014" title="">Analysis 1.7</a>), based on data from the same studies. </p> </section> <section id="CD002878-sec-0078"> <h6 class="title">12 months' follow‐up</h6> <p>Four studies provided the IPD of 236 participants for the FEV<sub>1</sub> and of 235 participants for the FVC (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). Participants in both groups showed no change in FEV<sub>1</sub> after 12 months (AMD 0.00 L, 95% CI ‐0.04 to 0.04; <a href="#CD002878-tbl-0003">Table 1</a>). For the FVC a comparable decrease was observed in participants of both groups (AMD ‐0.03 L, 95% CI ‐0.14 to 0.08; <a href="#CD002878-tbl-0003">Table 1</a>). The meta‐analyses did not include any additional data and yielded similar results for the FEV<sub>1 </sub>(MD 0.00 L, 95% CI ‐0.04 to 0.04; P = 0.61, I<sup>2</sup> = 0%; 4 studies, 236 participants; <a href="./references#CD002878-fig-0012" title="">Analysis 1.5</a>), and for the FVC (MD ‐0.02 L, 95% CI ‐0.13 to 0.09; P = 0.83, I<sup>2</sup> = 0%; 4 studies, 235 participants; <a href="./references#CD002878-fig-0013" title="">Analysis 1.6</a>). </p> <p>The RV/%TLC was measured in 197 participants in four studies (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>), and no treatment effect could be observed (AMD 0.4 %, 95% CI ‐2.1 to 2.9; <a href="#CD002878-tbl-0003">Table 1</a>). The MD obtained from the meta‐analysis of the RV/%TLC data was 0.27 % (95% CI ‐1.98 to 2.53; P = 0.96, I<sup>2</sup> = 0%; 4 studies, 195 participants; <a href="./references#CD002878-fig-0014" title="">Analysis 1.7</a>), based on data of the same four studies. </p> </section> </section> <section id="CD002878-sec-0079"> <h5 class="title">Respiratory muscle function</h5> <section id="CD002878-sec-0080"> <h6 class="title">Three months' follow‐up</h6> <p>Five studies with a total of 123 participants measured the PEmax (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). On average, the PEmax improved more in participants treated with NIV compared to participants allocated to the control group (AMD 3.7 cmH<sub>2</sub>O, 95% CI ‐4.2 to 11.6; <a href="#CD002878-tbl-0003">Table 1</a>). The PImax was measured in one additional study (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>), so 152 participants contributed IPD to this outcome. Both groups also showed an increase for the PImax, but AMD was 6.9 cmH<sub>2</sub>O (95% CI 2.3 to 11.5; <a href="#CD002878-tbl-0003">Table 1</a>) in favour of the NIV group. </p> <p>Respiratory muscle function data were available from one additional study (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>). In contrast to the pooled IPD analysis, the meta‐analyses revealed a larger and statistically significant effect on the PEmax (MD 9.03 cmH<sub>2</sub>O, 95% CI ‐1.51 to 19.58; P = 0.07, I<sup>2</sup> = 50%; 6 studies, 160 participants; <a href="./references#CD002878-fig-0015" title="">Analysis 1.8</a>). This outcome showed substantial statistical heterogeneity between the studies, which could not be explored by subgroup analysis as we included fewer than 10 studies. The meta‐analysis on the PImax showed comparable results to the pooled IPD analysis (MD 6.99 cmH<sub>2</sub>O, 95% CI 3.29 to 10.62, P = 0.99, I<sup>2</sup> = 0%; 7 studies, 192 participants; <a href="./references#CD002878-fig-0016" title="">Analysis 1.9</a>). </p> </section> <section id="CD002878-sec-0081"> <h6 class="title">12 months' follow‐up</h6> <p>The PEmax was only measured in one study (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>), and 38 participants contributed to the IPD. Data from this study showed a larger increase in PEmax in participants allocated to the NIV group (AMD 3.2 cmH<sub>2</sub>O, 95% CI ‐24.5 to 31.0; <a href="#CD002878-tbl-0003">Table 1</a>). Two studies measured the PImax (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>), and 92 participants contributed to the IPD. The effect after 12 months was comparable to the effect after three months, and was in favour of the NIV group (AMD 6.0 cmH<sub>2</sub>O, 95% CI ‐0.9 to 12.8; <a href="#CD002878-tbl-0003">Table 1</a>). </p> <p>There were no additional data available for the meta‐analyses of these outcomes. The meta‐analyses did not result in any new findings for the PEmax (MD 3.50 cmH<sub>2</sub>O, 95% CI ‐23.70 to 30.70; 1 study, 38 participants; <a href="./references#CD002878-fig-0015" title="">Analysis 1.8</a>), nor for the PImax (MD 7.04 cmH<sub>2</sub>O, 95% CI ‐12.29 to 26.37; P = 0.008, I<sup>2</sup> = 86%; 2 studies, 92 participants; <a href="./references#CD002878-fig-0016" title="">Analysis 1.9</a>). The results showed considerable statistical heterogeneity between the two studies, but this heterogeneity could not be explored by subgroup analysis due to the low number of studies. </p> </section> </section> <section id="CD002878-sec-0082"> <h5 class="title">Dyspnoea</h5> <section id="CD002878-sec-0083"> <h6 class="title">Three months' follow‐up</h6> <p>Three studies provided the IPD of 174 participants for the TDI (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>). One other study reported the TDI (<a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>), but we could not extract the aggregated data from the paper. The total score of the TDI ranges from ‐9 points (major deterioration) to +9 points (major improvement), and an improvement of one point has been established as clinically relevant (<a href="./references#CD002878-bbs2-0079" title="Witek T J Jr, MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267-72. [DOI: 10.1183/09031936.03.00068503a]">Witek 2003</a>). On average, participants allocated to both groups showed minor improvements (AMD 0.7, 95% CI ‐0.8 to 1.5; <a href="#CD002878-tbl-0003">Table 1</a>). Meta‐analysis yielded a comparable effect of NIV (MD 0.77, 95% CI 0.01 to 1.53; P = 0.34, I<sup>2</sup> = 8%; 3 studies, 178 participants; <a href="./references#CD002878-fig-0017" title="">Analysis 1.10</a>) but in contrast to the pooled IPD analysis, this effect was statistically significant. </p> <p>Four studies measured dyspnoea using the (modified)MRC (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>), and the IPD were available for 155 participants. The mMRC is reported on a 0 to 4 scale, with a score of 4 indicating severe dyspnoea. This outcome was not normally distributed, hence we could not conduct the linear mixed‐effect models. We included summary data of the same four studies in the meta‐analysis, which showed a decrease in the mMRC in participants allocated to NIV (MD ‐0.29, 95% CI ‐0.59 to 0.01; P = 0.21, I<sup>2</sup> = 34%; 4 studies, 155 participants; <a href="./references#CD002878-fig-0018" title="">Analysis 1.11</a>). We observed some statistical heterogeneity between the studies, but this was not considered important. </p> </section> <section id="CD002878-sec-0084"> <h6 class="title">12 months' follow‐up</h6> <p>None of the studies measured the TDI. Two studies measured dyspnoea using a 6‐point MRC (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>), and the IPD were available for 103 participants. Due to a non‐normal distribution, we did not conduct the linear mixed‐effects models. The meta‐analysis of this data showed a decrease in dyspnoea in participants treated with NIV (MD ‐0.49, 95% CI ‐0.90 to ‐0.08; P = 0.45, I<sup>2</sup> = 0%; 2 studies, 103 participants; <a href="./references#CD002878-fig-0018" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD002878-sec-0085"> <h5 class="title">Sleep efficiency</h5> <p>We did not find any new data since the original review was performed for this outcome. For consistency, we re‐analysed the data using the current linear mixed‐effect models. </p> <section id="CD002878-sec-0086"> <h6 class="title">Three months' follow‐up</h6> <p>Three studies with 24 participants provided IPD for sleep efficiency (<a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0015" title="Meecham JonesD , PaulEA , JonesPW , WedzichaJA . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. American Journal of Respiratory and Critical Care Medicine1995;152(152):538-44. Meecham JonesDJ , PaulEA , WedzichaJA . Nocturnal nasal pressure support ventilation with supplemental oxygen therapy compared with oxygen therapy alone in stable hypercapnic COPD — a randomised controlled study: effects on sleep and overnight blood gases. European Respiratory Journal1994;7(Suppl 18):461s. ">Meecham Jones 1995</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). Participants allocated to both groups showed an improvement in sleep efficiency, but the effect tended to be larger in participants allocated to the control group (AMD ‐7.9, 95% CI ‐21.6 to 5.8; <a href="#CD002878-tbl-0003">Table 1</a>). The meta‐analysis of data from the same studies showed a MD of ‐2.86% (95% CI ‐8.76 to 3.04; P = 0.37, I<sup>2</sup> = 0%; 3 studies, 24 participants; <a href="./references#CD002878-fig-0019" title="">Analysis 1.12</a>). </p> </section> <section id="CD002878-sec-0087"> <h6 class="title">12 months' follow‐up</h6> <p>None of the included studies measured sleep efficiency as “the percentage time asleep of the total time in bed”, with a follow‐up of 12 months. </p> </section> </section> <section id="CD002878-sec-0088"> <h5 class="title">COPD exacerbations and hospital admissions</h5> <p>Baseline hospital admission rates were not recorded, or were recorded over different time frames (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>). We were unable to perform the linear mixed‐effect models as this outcome was not normally distributed. </p> <section id="CD002878-sec-0089"> <h6 class="title">Three months' follow‐up </h6> <p>One study provided the IPD of 56 participants (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>). On average, exacerbations did not occur frequently in participants allocated to either group (<a href="#CD002878-tbl-0003">Table 1</a>). The number of participants that experienced an exacerbation was similar in participants allocated to the NIV group (12 of 24 participants (50%) ≥ 1 exacerbation) and the control group (19 of 32 participants (59%) ≥ 1 exacerbation) (OR 0.69, 95% CI 0.23 to 2.0). Aggregated exacerbation data from <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a> were available for the meta‐analysis. The OR for an exacerbation was 0.76 (95% CI 0.34 to 1.69; P = 0.77, I<sup>2</sup> = 0%; 2 studies, 100 participants; <a href="./references#CD002878-fig-0020" title="">Analysis 1.13</a>), in favour of participants treated with NIV. </p> <p>Four studies provided the IPD on hospital admissions of 268 participants (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>). Hospital admissions for respiratory causes were rare in participants of both groups (<a href="#CD002878-tbl-0003">Table 1</a>). An equal number of participants had been admitted to the hospital (NIV group: 34 of 137 participants (25%) admitted; control group: 34 of 131 participants (26%) admitted) (OR 0.89, 95% CI 0.51 to 1.57). Aggregated data from one additional study were available for the meta‐analysis (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>). The OR for a hospitalisation was 0.64 (95% CI 0.26 to 1.60; P = 0.10, I<sup>2</sup> = 49%; 5 studies, 312 participants; <a href="./references#CD002878-fig-0021" title="">Analysis 1.14</a>), in favour of participants treated with NIV. The results showed moderate statistical heterogeneity between the studies. </p> </section> <section id="CD002878-sec-0090"> <h6 class="title">12 months' follow‐up</h6> <p>One study provided the IPD on COPD exacerbations of 45 participants (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>). The median number of exacerbations was similar in both groups (<a href="#CD002878-tbl-0003">Table 1</a>). The number of participants that experienced an exacerbation appeared similar in participants allocated to the NIV group (15 of 18 participants (83%) ≥ 1 exacerbation) and the control group (25 of 27 participants (93%) ≥ 1 exacerbation) (OR 0.36, 95% CI 0.05 to 2.47). For the meta‐analysis, the aggregated data of <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a> could be included. The OR for an exacerbation favoured participants allocated to NIV (OR 0.72, 95% CI 0.25 to 2.05; P = 0.47, I<sup>2</sup> = 0%; 2 studies, 89 participants; <a href="./references#CD002878-fig-0020" title="">Analysis 1.13</a>). </p> <p>Data on hospital admissions were provided for 138 participants (<a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>). In the first study year, admissions for respiratory causes were rare (<a href="#CD002878-tbl-0003">Table 1</a>). A similar number of participants had been admitted to the hospital (NIV group: 30 of 71 participants (42%) admitted; control group: 26 of 67 participants (39%) admitted) (OR 1.14, 95% CI 0.58 to 2.25). For the meta‐analysis, the aggregated data of <a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a> could be included. There was no effect of NIV (OR 1.06, 95% CI 0.46 to 2.44; P = 0.18, I<sup>2</sup> = 39%; 4 studies, 182 participants; <a href="./references#CD002878-fig-0021" title="">Analysis 1.14</a>). There was some statistical heterogeneity between the studies, but we did not consider this to be important. </p> </section> </section> <section id="CD002878-sec-0091"> <h5 class="title">All‐cause mortality</h5> <p>Three studies provided the mortality data of 405 participants, with a median follow‐up of 30 months (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0011" title="KohnleinT , CrieeCP , KohlerD , WelteT , Laier-GroeneveldG . Multicenter Study on “Non-Invasive Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease and Emphysema(COPD)” [Multizentrische Studie: „Nicht-invasive Beatmung bei Patienten mit schwerer chronisch obstruktiver Bronchitis und Emphysem (COPD)”]. Pneumologie2004;58(8):566-9. [DOI: 10.1055/s-2004-818542]KohnleinT , WindischW , KohlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [PMID: 25066329]">Köhnlein 2014</a>; <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>). There was a lower risk for all‐cause mortality in participants treated with NIV (adjusted hazard ratio (AHR) 0.75, 95% CI 0.58 to 0.97). Mortality was reported by one additional study (<a href="./references#CD002878-bbs2-0002" title="CasanovaC , CelliBR , TostL , SorianoE , AbreuJ , VelascoV , et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with COPD. Chest2000;118(6):1582-90. CasanovaC , TostL , SorianoE , AbreuJ , HernandezMC , VelascoMV , et al. Night time nasal ventilation with BiPAPs for severe COPD in stable phase. Archivos de bronconeumologia1997;33((suppl 1)):44-46. MacarioC , CasanovaL , TostE , SorianoE , AbreuJ , VelascoMV , et al. Nocturnal nasal ventilation with BiPAPs in severe stable COPD. European Respiratory Journal1997;10 Suppl 25(Suppl 25):78S. MacarioCC , AbreuJ , SorianoE , TostL , AcostaO , Garcia TalaveraI , et al. Nocturnal nasal ventilation with BiPAP in stable severe COPD: a long term study. European Respiratory Journal1995;8 Suppl 19(Suppl 19):402S. ">Casanova 2000</a>), but we could not extract the data or source it from the authors. The meta‐analysis demonstrated a survival benefit for participants treated with NIV, but in contrast to the IPD analysis, this estimate was not statistically significant (HR 0.78, 95% CI 0.58 to 1.05; P = 0.29, I<sup>2</sup> = 20%; 3 studies, 405 participants; moderate‐certainty evidence; <a href="./references#CD002878-fig-0022" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD002878-sec-0092"> <h4 class="title">Post‐exacerbation COPD — primary outcomes</h4> <p>The absolute changes in all outcomes of participants commenced on NIV following an acute exacerbation is presented in <a href="#CD002878-tbl-0004">Table 2</a>.  In <a href="#CD002878-fig-0005">Figure 5</a>, the modelled means obtained from the linear mixed‐effect models are presented for the primary outcomes.  </p> <div class="table" id="CD002878-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in post‐exacerbation COPD, separate for the NIV and the control group</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>3 months</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>12 months</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaO<sub>2</sub> (kPa)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.08 ± 2.33 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.19 ± 2.12 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.21 ± 1.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.48 ± 2.10 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaCO<sub>2</sub> (kPa)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.99 ± 1.24 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.59 ± 1.19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐1.12 ± 1.15 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.61 ± 1.20 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SRI, summary score</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4.7 ± 10.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.7 ± 11.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4.8 ± 11.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.7 ± 11.8 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> (l)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.02 ± 0.19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.04 ± 0.20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.01 ± 0.21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.03 ± 0.22 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FVC (l)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.01 ± 0.66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.12 ± 0.63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.01 ± 0.64 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.08 ± 0.68 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>COPD exacerbations <sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 [0 to 1.0]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 [0 to 1.0] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.0 [1.0 to 4.0]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.0 [1.0 to 4.0] </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>COPD hospitalisations <sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 (0 to 2.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 (0 to 2.0)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data are based on the studies that provided the IPD, and are presented as mean ± standard deviation or median (interquartile range).  </p> <p><sup>a</sup> absolute number of exacerbations or hospitalisations. </p> <p>CI: confidence interval; COPD: Chronic Obstructive Pulmonary Disease; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; NIV: noninvasive ventilation; PaCO<sub>2</sub>: arterial carbon dioxide tension; PaO<sub>2</sub>: arterial oxygen tension; SRI: Severe Respiratory Insufficiency questionnaire, an increase indicates an improved health‐related quality of life. </p> </div> </div> <div class="figure" id="CD002878-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in post‐exacerbation COPD Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL." data-id="CD002878-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in post‐exacerbation COPD  </p> <p>Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL. </p> </div> </div> </div> <section id="CD002878-sec-0093"> <h5 class="title">Daytime arterial blood gas tensions</h5> <section id="CD002878-sec-0094"> <h6 class="title">Three months' follow‐up </h6> <p>Three studies provided the IPD for the arterial blood gases of 234 participants for the PaO<sub>2</sub> and for 241 participants for the PaCO<sub>2</sub> (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). There was no difference on the change in PaO<sub>2</sub> between participants allocated to NIV or standard care (AMD ‐0.10 kPa, 95% CI ‐0.65 to 0.45; <a href="#CD002878-tbl-0004">Table 2</a>). There were improvements in the PaCO<sub>2</sub> in both groups, but the effect was larger in participants treated with NIV (AMD ‐0.40 kPa, 95% CI ‐0.70 to ‐0.09; <a href="#CD002878-tbl-0004">Table 2</a>). </p> <p>The meta‐analyses of these outcomes were based on data of the same three studies and yielded comparable results to the pooled IPD analyses for both the PaO<sub>2</sub> (MD ‐0.08 kPa, 95% CI ‐0.58 to 0.41; P = 0.85, I<sup>2</sup> = 0%; 3 studies, 234 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0026" title="">Analysis 2.1</a>) and PaCO<sub>2</sub> (MD ‐0.42 kPa, 95% CI ‐0.72 to ‐0.12; P = 0.45, I<sup>2</sup> = 0%; 3 studies, 241 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0027" title="">Analysis 2.2</a>). </p> </section> <section id="CD002878-sec-0095"> <h6 class="title">12 months' follow‐up </h6> <p>The same three studies provided the IPD of 170 participants for the PaO<sub>2</sub> and of 175 participants for the PaCO<sub>2</sub> (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>) . In the control group, PaO<sub>2</sub> tended to improve more compared to participants in the NIV group (AMD ‐0.27 kPa, 95% CI ‐0.86 to 0.32; <a href="#CD002878-tbl-0004">Table 2</a>). In contrast, the PaCO<sub>2</sub> was reduced in both groups, but the effect was larger in the participants treated with NIV (AMD ‐0.52 kPa, 95% CI ‐0.87 to ‐0.18; <a href="#CD002878-tbl-0004">Table 2</a>). </p> <p>The meta‐analyses of these outcomes were based on data from the same three studies and yielded comparable results to the pooled IPD analyses for both the PaO<sub>2</sub> (MD ‐0.24 kPa, 95% CI ‐0.81 to 0.34; P = 0.64, I<sup>2</sup> = 0%; 3 studies, 170 participants; moderate certainty evidence; <a href="./references#CD002878-fig-0026" title="">Analysis 2.1</a>) and PaCO<sub>2</sub> (MD ‐0.53 kPa, 95% CI ‐0.88 to ‐0.19; P = 0.94, I<sup>2</sup> = 0%; 3 studies, 175 participants; high‐certainty evidence; <a href="./references#CD002878-fig-0027" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD002878-sec-0096"> <h5 class="title">Health‐related quality of life</h5> <section id="CD002878-sec-0097"> <h6 class="title">Three months' follow‐up </h6> <p>Two studies provided the IPD of 216 participants for the SRI (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). Additional IPD of the SGRQ were available for three participants (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>), so we standardised and pooled the data of the SRI and SGRQ. Participants treated with NIV improved more on the summary score of the SRI compared to participants allocated to the control group (<a href="#CD002878-tbl-0004">Table 2</a>). After pooling of the SRI and SGRQ data, there was no added benefit of the NIV on HRQL (AMD 0.25, 95% CI ‐0.01 to 0.51). Given a SD of 11.2 units for the SRI, this would suggest an improvement of 2.8 units. </p> <p>The meta‐analysis of aggregated data from the same two studies showed a SMD in favour of the NIV group (SMD 0.27, 95% CI 0.01 to 0.54; P = 0.63, I<sup>2</sup> = 0%; 2 studies, 216 participants; very low‐certainty evidence; <a href="./references#CD002878-fig-0028" title="">Analysis 2.3</a>). In contrast to the pooled IPD analysis, this was statistically significant.  </p> </section> <section id="CD002878-sec-0098"> <h6 class="title">12 months' follow‐up</h6> <p>SRI data were available for 162 participants of the same two studies (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). Participants treated with NIV showed, on average, a larger improvement on the summary score of the SRI (<a href="#CD002878-tbl-0004">Table 2</a>). Additional IPD of the SGRQ were available for two participants (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>), so we standardised and pooled the data.  In line with the three‐month data, there was no added benefit of the NIV on HRQL (AMD 0.25, 95% CI ‐0.06 to 0.55). Given a SD of 11.9 units for the SRI, this would suggest an improvement of 3.0 units. </p> <p>The meta‐analysis yielded similar results to the pooled IPD analysis (SMD 0.27, 95% CI ‐0.04 to 0.58; P = 0.34, I<sup>2</sup> = 0%; 2 studies, 162 participants; very low‐certainty evidence; <a href="./references#CD002878-fig-0028" title="">Analysis 2.3</a>). </p> </section> </section> </section> <section id="CD002878-sec-0099"> <h4 class="title">Admission‐free survival</h4> <p>This outcome was measured as time from randomisation to readmission (for a pulmonary cause) or death (of any cause) in the first year after randomisation in two studies (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). The trials provided data from 317 participants. The admission‐free survival was better in participants treated with NIV compared to participants allocated to the control group (AHR 0.71, 95% CI 0.54 to 0.94). </p> <p>The meta‐analysis of data of the same studies demonstrated an admission‐free survival benefit favouring the NIV group, but in contrast to the pooled IPD analysis this effect was not statistically significant (HR 0.69, 95% CI 0.39 to 1.23; P = 0.05, I<sup>2</sup> = 75%; 2 studies, 317 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0029" title="">Analysis 2.4</a>). The results showed considerable statistical heterogeneity between the studies, but this heterogeneity could not be explored by subgroup analysis due to the low number of studies. </p> </section> <section id="CD002878-sec-0100"> <h4 class="title">Post exacerbation COPD — secondary outcomes</h4> <section id="CD002878-sec-0101"> <h5 class="title">Lung function</h5> <section id="CD002878-sec-0102"> <h6 class="title">Three months' follow‐up </h6> <p>Two studies provided the IPD of 204 participants for this outcome (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). For the FEV<sub>1</sub>, both study groups showed only a minor increase, the increase probably being slightly larger in participants allocated to the control group (AMD ‐0.02 L, 95% CI ‐0.07 to 0.03; <a href="#CD002878-tbl-0004">Table 2</a>). In contrast, an increase in the FVC was only observed in participants allocated to the control group (AMD ‐0.11 L, 95% CI ‐0.28 to 0.06; <a href="#CD002878-tbl-0004">Table 2</a>). The meta‐analyses were based on the same two studies that provided the IPD and did not reveal any new findings for both the FEV<sub>1</sub> (MD ‐0.03 L, 95% CI ‐0.09 to 0.03; P = 0.28, I<sup>2</sup> = 14%; 2 studies, 201 participants; <a href="./references#CD002878-fig-0030" title="">Analysis 2.5</a>) and the FVC (MD ‐0.13 L, 95% CI ‐0.32 to 0.04; P = 0.61, I<sup>2</sup> = 0%; 2 studies, 202 participants; <a href="./references#CD002878-fig-0031" title="">Analysis 2.6</a>). </p> </section> <section id="CD002878-sec-0103"> <h6 class="title">12 months' follow‐up</h6> <p>The results of the 157 participants from the same two studies yielded similar results. Both study groups showed only minor changes in the FEV<sub>1</sub> (AMD ‐0.03 L, 95% CI ‐0.09 to 0.04; <a href="#CD002878-tbl-0004">Table 2</a>). The change in the FVC tended to be in favour of the control group (AMD ‐0.09 L, 95% CI ‐0.29 to 0.12; <a href="#CD002878-tbl-0004">Table 2</a>), as the FVC in the NIV group seems not affected. </p> <p>The meta‐analyses yielded comparable results for the FEV<sub>1</sub> (MD ‐0.03 L, 95% CI ‐0.09 to 0.03; P = 0.62, I<sup>2</sup> = 0%; 2 studies, 157 participants; <a href="./references#CD002878-fig-0030" title="">Analysis 2.5</a>) and the FVC (MD ‐0.11 L, 95% CI ‐0.32 to 0.10; P = 0.29, I<sup>2</sup> = 9%; 2 studies, 158 participants; <a href="./references#CD002878-fig-0031" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD002878-sec-0104"> <h5 class="title">COPD exacerbations and hospital admissions</h5> <p>Baseline hospital admission rates were recorded in two studies (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>) for the 12 months before inclusion in the study but in one study it was only recorded whether there were &lt; 3 or ≥ 3 admissions. We were unable to perform the linear mixed effect models as this outcome was not normally distributed. </p> <section id="CD002878-sec-0105"> <h6 class="title">Three months' follow‐up </h6> <p>One study provided the IPD of 139 participants (<a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). On average, the total numbers of COPD exacerbations appear to be equal between both groups (<a href="#CD002878-tbl-0004">Table 2</a>). An equal proportion of participants had experienced one or more exacerbation (NIV group: 35 of 76 participants (46%); control group: 31 of 68 participants (46%) ≥ 1 exacerbation). The OR for an exacerbation was 0.93 (95% CI 0.47 to 1.81) in favour of participants in the NIV group. The meta‐analysis of data of the same study yielded also an OR of 0.93 (95% CI 0.48 to 1.81; 1 study, 139 participants; <a href="./references#CD002878-fig-0032" title="">Analysis 2.7</a>). </p> <p>Hospitalisation data were not available for any of the included studies after three months. </p> </section> <section id="CD002878-sec-0106"> <h6 class="title">12 months' follow‐up</h6> <p>Three studies contributed COPD exacerbation data of 181 participants (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>). There was an equal number of COPD exacerbations in both groups during the study period (<a href="#CD002878-tbl-0004">Table 2</a>). Also, exacerbation rates appeared similar between participants allocated to NIV (73 of 95 participants (77%) ≥ 1 exacerbation) and to the control group (71 of 86 participants (83%) ≥ 1 exacerbation). The OR was in favour of participants allocated to NIV (OR 0.70, 95% CI 0.33 to 1.46). Meta‐analysis of data of the same three studies showed a comparable result to the IPD analysis (OR 0.67, 95% CI 0.32 to 1.41; P = 0.98, I<sup>2</sup> = 0%; 3 studies, 181 participants; <a href="./references#CD002878-fig-0032" title="">Analysis 2.7</a>). </p> <p>IPD regarding hospital admissions were available for 193 participants of the same three studies. There was no difference in the number of hospital admissions (<a href="#CD002878-tbl-0004">Table 2</a>). Admission rates appeared similar between participants treated with NIV (54 of 100 participants (54%) admitted) and participants allocated to the control group (53 of 93 participants (57%) admitted). The OR for a hospitalisation was 0.88 (95% CI 0.52 to 1.50) in favour of participants treated with NIV. In the meta‐analysis, we observed a larger OR (OR 0.63, 95% CI 0.19 to 2.09; P = 0.06, I<sup>2</sup> = 66%; 3 studies, 193 participants; <a href="./references#CD002878-fig-0033" title="">Analysis 2.8</a>). These results may represent substantial statistical heterogeneity between the studies, but this heterogeneity could not be explored due to the low number of studies. </p> </section> </section> <section id="CD002878-sec-0107"> <h5 class="title">All‐cause mortality</h5> <p>All‐cause mortality was measured in two studies (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0019" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. Nocturnal noninvasive ventilation in COPD patients who remain hypercapnic after ventilatory support for an acute respiratory failure: a randomized, controlled, parallel-group study. In: American Journal of Respiratory and Critical Care Medicine. Vol. 189. 2014:A1174. StruikFM , SprootenRT , KerstjensHA , BladderG , ZijnenM , SinJA , et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax2014;69(9):826-34. ">Struik 2014</a>), which provided the IPD of 317 participants. The median follow‐up of all participants was 21 months. The risk for all‐cause mortality was not affected by NIV (AHR 0.97, 95% CI 0.74 to 1.28). The meta‐analysis of the mortality data of the same two studies yielded similar results to the pooled IPD analysis (HR 0.98, 95% CI 0.74 to 1.29; P = 0.96, I<sup>2</sup> = 0%; 2 studies, 317 participants; low‐certainty evidence; <a href="./references#CD002878-fig-0034" title="">Analysis 2.9</a>). </p> </section> </section> <section id="CD002878-sec-0108"> <h4 class="title">Heterogeneity exploration in PaCO<sub>2</sub> response in stable state </h4> <p>In the stable population, the results of the PaCO<sub>2</sub> analysis after three months demonstrated substantial statistical heterogeneity (P = 0.001; I<sup>2</sup> = 65%;  <a href="./references#CD002878-fig-0009" title="">Analysis 1.2</a>). Subgroup analysis based on the mean baseline PaCO<sub>2</sub> of the study revealed a significant subgroup difference (test for subgroup differences: P = 0.001; I<sup>2</sup> = 91%; <a href="./references#CD002878-fig-0023" title="">Analysis 1.16</a>; <a href="#CD002878-fig-0006">Figure 6</a>). In the PaCO<sub>2</sub> &lt; 7.3 kPa subgroup, heterogeneity was reduced to 0%, but remained substantial in the ≥ 7.3 kPa subgroup. As seen in <a href="#CD002878-fig-0006">Figure 6</a>, the study by <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a> seems to cause this heterogeneity. This was the only study in this subgroup adopting low ventilator pressures (mean IPAP &lt; 18 cmH<sub>2</sub>O), and when this study was removed from the subgroup, the heterogeneity was reduced to 0% (P = 0.64). </p> <div class="figure" id="CD002878-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD002878-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Additional subgroup analysis based on mean IPAP also found significant subgroup differences (test for subgroup differences: P = 0.005, I<sup>2</sup> = 88%; <a href="./references#CD002878-fig-0024" title="">Analysis 1.17</a>; <a href="#CD002878-fig-0007">Figure 7</a>). In the IPAP &lt; 18 cmH<sub>2</sub>O subgroup, the heterogeneity was reduced to 0% (P = 0.55), whilst in the IPAP ≥ 18 cmH<sub>2</sub>O subgroup, the heterogeneity remained substantial. As seen in <a href="#CD002878-fig-0007">Figure 7</a>, the study by <a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a> seems to cause this heterogeneity. This study mainly included participants with moderate hypercapnia (mean baseline PaCO<sub>2</sub> &lt; 7.3 kPa), and removal of this study from the subgroup reduced the heterogeneity to 0% (P = 0.64). </p> <div class="figure" id="CD002878-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="original image" data-id="CD002878-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Lastly, subgroup analysis based on compliance also showed significant subgroup differences (test for subgroup differences: P = 0.04, I<sup>2</sup> = 77%; <a href="./references#CD002878-fig-0025" title="">Analysis 1.18</a>), but the heterogeneity in the good compliance subgroup remained substantial (P = 0.01, I<sup>2</sup> = 59%). </p> </section> <section id="CD002878-sec-0109"> <h4 class="title">Sensitivity analysis</h4> <p>For the sensitivity analysis we excluded seven studies on stable COPD as we had judged these to be at high or unclear risk of bias for the selection or attrition domain (or both) (<a href="./references#CD002878-bbs2-0001" title="BhattSP , PetersonMW ,  WilsonJS , DurairajL . Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. International Journal of COPD2013;8:581-9. [PMID: PMC3842217]NCT01722773. Trial of non-invasive ventilation for stable COPD. clinicaltrials.gov/ct2/show/NCT01722773 (first received 7 November 2012). ">Bhatt 2013</a>; <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>; <a href="./references#CD002878-bbs2-0020" title="StrumpfDA , MillmanRP , CarlisleCC . Nocturnal positive pressure ventilation via nasal mask in patients with COPD. American Review of Respiratory Disease1991;144:1234-9. ">Strumpf 1991</a>). Removal of these studies from the analysis resulted in a slightly larger treatment effect for PaO<sub>2</sub> after three months of NIV (AMD 0.31 kPa, 95% CI 0.02 to 0.62, 103 participants), but did not affect the PaO<sub>2</sub> results after 12 months. The treatment effect of NIV on PaCO<sub>2</sub> increased both after three months' follow‐up (AMD ‐0.76 kPa, 95% CI ‐0.98 to ‐0.55, 304 participants) and 12 months' follow‐up (AMD ‐0.55 kPa, 95% CI ‐0.84 to ‐0.27, 174 participants). The sensitivity analysis also revealed a larger and statistically significant effect of NIV on the 6MWD, both after three months (AMD 22.3 m, 95% CI 2.1 to 42.5, 245 participants) and after 12 months (AMD 44.0m, 95% CI 0.2 to 87.8, 88 participants). Lastly, a larger effect of NIV was observed on HRQL at both follow‐ups (three months: AMD 0.44, 95% CI 0.18 to 0.68, 229 participants; 12 months: AMD 0.26, 95% CI ‐0.05 to 0.55; 169 participants). </p> <p>We excluded one post‐exacerbation study due to high or unclear risk of bias (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>). When limiting the analysis to the remaining high‐quality studies, the treatment effects for all primary outcomes were in line with the overall treatment effect in this cohort. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002878-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002878-sec-0110"></div> <section id="CD002878-sec-0111"> <h3 class="title" id="CD002878-sec-0111">Summary of main results</h3> <p>In people with severe COPD in a stable condition, the addition of chronic NIV to standard treatment improves diurnal hypercapnia (high‐certainty evidence) for up to 12 months. Additionally, chronic NIV seems to improve short‐term diurnal PaO<sub>2</sub> and all‐cause mortality (moderate‐certainty evidence) and might result in a relevant improvement in HRQL at three months (very low‐certainty evidence).  In people who have COPD with persistent hypercapnia following a severe COPD exacerbation with AHRF, the added benefit of chronic NIV seems to be more limited. In this population, chronic NIV seems to improve daytime hypercapnia (moderate to high‐certainty evidence) and might prolong the time to readmission or death (low‐certainty evidence), without a beneficial effect on HRQL. Although the targets of this treatment seem to differ between these populations, the results of this systematic review seem to confirm the application of chronic NIV in people with COPD in a stable clinical state, and might support the initiation of chronic NIV in people who have COPD with persistent hypercapnia after an acute exacerbation of COPD. </p> <section id="CD002878-sec-0112"> <h4 class="title">Interpretation of the main findings</h4> <section id="CD002878-sec-0113"> <h5 class="title">Gas exchange</h5> <p>The evidence indicates that regardless of the timing of chronic NIV initiation, relevant improvements in hypercapnia may be achieved with chronic NIV. Additionally, the PaO<sub>2</sub> of people with stable COPD seems to improve with NIV after three months. Our results again indicate that that in stable COPD, the effect of NIV on diurnal ventilation seems to be larger in people with more severe hypercapnia (PaCO<sub>2</sub> ≥ 7.3 kPa) and a better treatment compliance (≥ 5 hours per night) (<a href="./references#CD002878-bbs2-0069" title="StruikFM , LacasseY , GoldsteinRS , KerstjensHA , WijkstraPJ . Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respiratory Medicine2014;108(2):329-37. [DOI: 10.1016/j.rmed.2013.10.007]">Struik 2014</a>). Hypercapnia also seems to improve more in people treated with an IPAP ≥ 18 cmH<sub>2</sub>O. This finding supports the application of NIV adopting high IPAP to target nocturnal PaCO<sub>2</sub> reduction, which has become a major NIV strategy during the past decade (<a href="./references#CD002878-bbs2-0044" title="DreherM , StorreJH , SchmoorC , WindischW . High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax2010;65(4):303-8.">Dreher 2010</a>; <a href="./references#CD002878-bbs2-0077" title="WindischW , HaenelM , StorreJH , DreherM . High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. International Journal of Medical Sciences2009;6(2):72-6. [DOI: 10.7150/ijms.6.72]">Windisch 2009</a>). However, it remains uncertain to what extent these improvements in gas exchange contribute to the beneficial effect on individual‐centred outcomes such as HRQL and survival. A better understanding of these mechanisms could improve selection of people with COPD for NIV, and could optimise the titration of the individual's NIV settings. Therefore, we emphasise this should be an aim of future studies. </p> </section> <section id="CD002878-sec-0114"> <h5 class="title">Exercise capacity</h5> <p>Evidence that chronic NIV improves exercise capacity is currently insufficient. However, if only high‐quality studies are included, it seems that there is a benefit of chronic NIV on the exercise capacity at both three months (AMD 22.3 m, 95% CI 2.1 to 42.5) and 12 months' follow‐up (AMD 44.0 m, 95% CI 0.2 to 87.8). Given the MCID of 26 m identified in this population of people with very severe COPD (<a href="./references#CD002878-bbs2-0059" title="PuhanMA , ChandraD , MosenifarZ , RiesA , MakeB , HanselNN , et al. The minimal important difference of exercise tests in severe COPD. European Respiratory Journal2011;37 Suppl:748-90. [DOI: 10.1183/09031936.00063810]">Puhan 2011</a>), this improvement only seems to be of relevance after 12 months. We acknowledge that the uncertainty in these estimates is high, as the 95% CI are wide. So although there might be a positive effect, a definite conclusion about the effect of chronic NIV on exercise capacity cannot be drawn at this moment. </p> </section> <section id="CD002878-sec-0115"> <h5 class="title">Health‐related quality of life</h5> <p>Improving HRQL should be a major target of any treatment in severe or end‐stage COPD. Acknowledging that our confidence in the evidence is very low, the results do indicate that the initiation on chronic NIV might have a beneficial effect on HRQL in people with stable COPD in the short term. This treatment effect after three months seems to reach clinical relevance, at least when measured with the change responsive SRI. The contrasting results at the 3‐ and 12‐month follow‐up periods are interesting. We emphasise that different proportions of studies contributed to either follow‐up, possibly with different treatment and participant characteristics, which might explain these different results. For participants initiated following an exacerbation, there seems to be no benefit of NIV on HRQL and only the upper range of the 95% CI seems to be of clinically relevance for the total score of the SRI. Future studies should therefore continue to investigate the effect of post‐exacerbation chronic NIV on HRQL and identify which individual is most likely to experience a HRQL benefit. Lastly, given the result of the meta‐analysis on the dyspnoea outcomes, there may be a small beneficial effect on dyspnoea, but the data are sparse and the effect estimate does not seem to reach clinical relevance (<a href="./references#CD002878-bbs2-0079" title="Witek T J Jr, MahlerDA . Minimal important difference of the transition dyspnoea index in a multinational clinical trial. European Respiratory Journal2003;21(2):267-72. [DOI: 10.1183/09031936.03.00068503a]">Witek 2003</a>). </p> </section> <section id="CD002878-sec-0116"> <h5 class="title">Exacerbations and (re)hospitalisations</h5> <p>We found that chronic NIV might prolong the admission‐free survival in people initiated on NIV following a severe COPD exacerbation. However, continuing NIV after an exacerbation did not affect the total number of COPD admissions in the first year, and did not affect mortality. We hypothesise that, although the first readmission might have been postponed, eventually these people with severe COPD suffer from frequent exacerbations and related mortality despite the chronic NIV. Furthermore, admission‐free survival was investigated in the total population, while exacerbation and admission rates were investigated only in the participants who completed the study period of one year. To conclude, at this moment there is insufficient evidence that chronic NIV following a severe COPD exacerbation reduces the number of COPD exacerbations and admissions, and mortality in these patients remains high. </p> </section> <section id="CD002878-sec-0117"> <h5 class="title">Mechanisms</h5> <p>It has been hypothesised that chronic NIV achieves its beneficial effect though improvements in respiratory mechanics, such as stabilisation of FEV<sub>1</sub> and a reduction in residual volume. The results of this review do not seem to be supportive of these hypotheses. We did not show an effect of NIV on different lung function outcomes in either of our cohorts. A second hypothesis concerns an improved function of the respiratory muscles that might be obtained by chronic NIV. The results of our analyses indicate an improved PImax. In people with severe COPD, PImax is known to be related to dyspnoea, HRQL and even survival (<a href="./references#CD002878-bbs2-0058" title="OttenheijmCA , HeunksLM , DekhuijzenRP . Diaphragm adaptations in patients with COPD. Respiratory Research2008;9(1):12. [DOI: 10.1186/1465-9921-9-12]">Ottenheijm 2008</a>), so an improved respiratory muscle function could contribute to the improved outcomes of NIV. It should, however, be noted that PImax measures maximum inspiratory pressure, which is a derivative of respiratory muscle strength and importantly also affected by hyperinflation (<a href="./references#CD002878-bbs2-0063" title="RochesterDF , BraunNM . Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. American Review of Respiratory Disease1985;132(1):42-7.">Rochester 1985</a>). However, we did not show an improvement in hyperinflation with NIV. In addition, due to its voluntary nature, these measurements are affected not only by strength but also by motivation (<a href="./references#CD002878-bbs2-0058" title="OttenheijmCA , HeunksLM , DekhuijzenRP . Diaphragm adaptations in patients with COPD. Respiratory Research2008;9(1):12. [DOI: 10.1186/1465-9921-9-12]">Ottenheijm 2008</a>). These caveats prevent strong conclusions regarding improved respiratory function by NIV, but our results do at least not refute this hypothesis. Finally, an effect on sleep quality might be an important aspect in improving HRQL. However, this has unfortunately seldom been investigated, and no additional data could be added to this meta‐analysis to support this hypothesis. </p> </section> </section> </section> <section id="CD002878-sec-0118"> <h3 class="title" id="CD002878-sec-0118">Overall completeness and applicability of evidence</h3> <p>This review included 21 RCTs investigating chronic NIV for people with severe COPD. Fortunately, the trial authors of 16 studies responded to our request to share their trial data, enabling the investigation of the IPD of 1142 participants.  We could not obtain the IPD from five trials. Therefore, we also conducted a meta‐analysis of the summary trial data from all trials. For the majority of the outcomes, the results of the meta‐analysis were in line with the IPD results, except for expiratory muscle strength after three months, which became significant after additional data were added (<a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>). In the post‐exacerbation population, the IPD of the admission‐free survival and mortality outcomes were not fully obtained, as these IPD were not provided for the study by <a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>. This trial might bias the results, as participants were excluded from the trial once the primary outcome (“an episode recurrent AHRF requiring acute NIV or intubation, or death”) was reached. Additionally, it remains unclear if the trial by <a href="./references#CD002878-bbs2-0032" title="XiangPC , ZiangPC , ZhangX , YangJN , ZhangEM , GouWA , et al. The efficacy and safety of long term home noninvasive positive pressure ventilation in patients with stable severe chronic obstructive pulmonary disease. Chinese Journal of Tuberculosis and Respiratory Diseases2007;30(10):746-50. ">Xiang 2007</a> could be included, as we were unable to contact the trial authors. </p> <p>The inclusion criteria were generally consistent between the studies, and all studies only included participants with severe COPD. The vast majority included participants with chronic hypercapnia; only 61 participants (8%) without hypercapnia were included. We therefore emphasise that the results apply primarily to people with COPD who experience chronic hypercapnia. In the stable population, 72% of the participants were male, which could reflect the higher prevalence of COPD in males (<a href="./references#CD002878-bbs2-0048" title="Global Strategy for the Diagnosis, Management and Prevention of COPD 2021. Global Initiative for Chronic Obstructive Lung Disease (GOLD). goldcopd.org/2021-gold-reports/2021.">GOLD 2021</a>; <a href="./references#CD002878-bbs2-0070" title="TerzikhanN , VerhammeKM , HofmanA , StrickerBH , BrusselleGG , LahousseL . Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. European Journal of Epidemiology2016;31(8):785-92. [DOI: 10.1007/s10654-016-0132-z]">Terzikhan 2016</a>). In contrast to the 2013 update, this review also included studies that investigated chronic nocturnal NIV in addition to a pulmonary rehabilitation or exercise training program. This increased the body of evidence as it resulted in the inclusion of four additional studies (<a href="./references#CD002878-bbs2-0007" title="DuivermanML , BladderG , WempeJB , KerstjensHA , ZijlstraJG , WijkstraPJ . Chronic ventilatory support improves the outcomes of rehabilitation in hypercapnic COPD patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008. DuivermanML , WempeJB , BladderG ,  VonkJ , KerstjensHA , WijkstraPJ . Two-year nocturnal noninvasive ventilation added to rehabilitation in hypercapnic COPD patients. American Journal of Respiratory and Critical Care Medicine2010;B44(181):A3056. [DOI: doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A3056]DuivermanML , WempeJB , BladderG , JansenDF , KerstjensHAM , ZijlstraJG , et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax2008;63(12):1052-7. [PMID: 18710905]DuivermanML , WempeJB , BladderG , VonkJM , ZijlstraJG , KerstjensHA , et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respiratory Research2011;12:112. [PMID: 21861914]">Duiverman 2008</a>; <a href="./references#CD002878-bbs2-0009" title="GarrodR , MikelsonsC , PaulEA , WedzichaJA . Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;162:1335-41. GarrodR , MikelsousC , PaulEA , WedzichaJA . Randomised controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe COPD. American Journal of Respiratory and Critical Care Medicine2000;61(Suppl 3):A255. ">Garrod 2000</a>; <a href="./references#CD002878-bbs2-0013" title="Marquez-MartinE , CejudoP , Lopez-CamposJL , RodriguezA , ValenciaB , BarrotE , et al. Home mechanical ventilation and respiratory rehabilitation: Influence in respiratory functional test and exercise capacity. European Respiratory Journal2012;40(Suppl 56):294s [P1710]. Marquez-MartinE , RuizFO , RamosPC , Lopez-CamposJL , AzconaBV , CortesEB . Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. Respiratory Medicine2014;108(12):1741-51. ">Martin‐Marquez 2014</a>; <a href="./references#CD002878-bbs2-0017" title="SchneebergerT , StegemannA , Schoenheit-KennU ,  JaroschI ,  GloecklR , KohnleinT , et al. Nocturnal non invasive ventilation as an adjunct for pulmonary rehabilitation in patients with very severe COPD — a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2017;195:A2851. ">Schneeberger 2017</a>), including the IPD of 127 participants. Our results cannot automatically be extended to overlap people who have COPD with concomitant obstructive sleep apnea, as most studies excluded people with concomitant sleep apnea or a very high BMI. Although this might limit the generalisability of our conclusions, in the present analysis effects for people with COPD are reliably displayed without overestimating the effects due to concomitant sleep apnea or serious obesity hypoventilation.   </p> <p>It should also be noted the majority of the studies, especially the larger studies and studies with positive outcomes, have been conducted in Europe. This could limit the generalisability of the results to other regions as expertise and organisation of care might differ, which could lead to differences in treatment characteristics, adherence and effectiveness. </p> </section> <section id="CD002878-sec-0119"> <h3 class="title" id="CD002878-sec-0119">Quality of the evidence</h3> <p>Overall, the certainty of the evidence for the main comparisons was moderate to very low, according to the  <a href="./references#CD002878-bbs2-0049" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group, October 2013.">GRADE 2013</a> recommendations. The PaCO<sub>2</sub> outcome was the only outcome that we judged to be of high certainty, and it is believed that the observed treatment effect lies close to the true treatment effect of NIV. Risk of bias was a major reason for downgrading the certainty, as the unblinded design of the included studies is likely to affect outcomes such as the 6MWD and HRQL. We decided not to downgrade the blood gas and survival outcomes on this domain, as we judged that the unblinded design is unlikely to affect these outcomes. Inconsistency was observed in two outcomes, but we did not consider this a reason to downgrade the certainty. First, we observed substantial statistical heterogeneity between the studies for the PaCO<sub>2</sub> outcome (P = 0.001, I<sup>2</sup> = 65%), but this could be explained by the subgroup analysis. Second, the admission‐free survival demonstrated considerable heterogeneity (P = 0.005, I<sup>2</sup> = 75%). As only two studies provided data for this outcome, we were unable to conduct subgroup analysis to explore this heterogeneity. Nevertheless, this heterogeneity may be explained by differences in the timing of NIV initiation and participant selection, as in both studies the intervention targeted nocturnal correction of hypoventilation and was initiated in highly experienced centres. Another major reason to downgrade the certainty was serious imprecision. For most outcomes, the number of studies was low, resulting in wide 95% CIs. Thus, the possibility of harm or no treatment effect could not be excluded for outcomes such as the 6MWD, HRQL and the survival outcomes. Lastly, we did not observe indirectness or publication bias in our results. </p> </section> <section id="CD002878-sec-0120"> <h3 class="title" id="CD002878-sec-0120">Potential biases in the review process</h3> <section id="CD002878-sec-0121"> <h4 class="title">Limitations regarding the setup of the analyses</h4> <p>Our protocol limited the follow‐up duration to three or 12 months of NIV. Two studies measured or reported trial outcomes only after six months of NIV, and we did not use these data (<a href="./references#CD002878-bbs2-0006" title="De BackerL , De BackerWA , VosW , De BackerJ , DaemsD , ClaesR , et al. Factors Determining Physiological Effects Of Non-Invasive Ventilation In Hypercapnic COPD Patients. In: European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. Vol. 183. 2011:A4575. De BackerL , VosW , DieriksB , DaemsD , VerhulstS , VinchurkarS , et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. International Journal of Chronic Obstructive Pulmonary Disease2011;6:615-24. [DOI: 10.2147/COPD.S22823]">De Backer 2011</a>; <a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>). The results of these two studies seem in line with the results of our review, with the exception that a relevant benefit was found on the 6MWD in stable COPD (<a href="./references#CD002878-bbs2-0008" title="Eman SheblR , AbderabohMM . Bi-level positive airway pressure ventilation for patients with stable hypercapnic chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis2015;64(2):395-8. [DOI: doi.org/10.1016/j.ejcdt.2015.02.004]">Eman Shebl 2015</a>). Although only 45 participants were included in these two studies, we acknowledge that this a limitation as it reduced the body of evidence. Another limitation is that we did not investigate serious or rare adverse effects. However, the (serious) adverse effects of chronic NIV are well known and are usually related to intolerance to the device or mask, leakage of the air delivered or facial irritation due to mask pressures. A recent review on chronic NIV supports this as it found an incidence rate of 0 per person (95% CI 0.00 to 0.01) for severe adverse events and of 0.21 per person (95% CI 0.12 to 0.37) for adverse events, acknowledging that a majority of the trials did not report adverse events (<a href="./references#CD002878-bbs2-0074" title="WilsonME , DoblerCC , MorrowAS , BeuschelB , AlsawasM , BenkhadraR , et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of the American Medical Association2020;323(5):455-65. [DOI: 10.1001/jama.2019.22343]">Wilson 2020</a>). Lastly, we could not assess the risk of publication bias as the only outcome with more than 10 included studies (PaCO<sub>2</sub>) demonstrated heterogeneity between the studies. </p> </section> <section id="CD002878-sec-0122"> <h4 class="title">Limitations regarding the included studies</h4> <p>We encountered several limitations regarding the included studies. The major limitation concerns the unblinded nature of the vast majority of the trials. Although some trials used a continuous positive airway pressure as sham device (<a href="./references#CD002878-bbs2-0003" title="CheungAP ,  ChanVL ,  LiongJT ,  LamJY ,  LeungWS ,  LinA ,  et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease2010;14(5):642-9. [PMID: 20392360]CheungAP , ChanVL , LiongJT , LamJY , LeungWS , LinA , et al. A randomised controlled trial of continuation of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in chronic obstructive airway disease. In: Respirology. Vol. 13. 2008:A120 (012-04). Chu C-M, CheungA , ChanV , LiongJ , Leung W-S, LinA . A randomised trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin. 2008:3665. ChuCM , CheungAP , ChanVL , LeungWS , LinAW . A randomized trial of home non-invasive ventilation vs sham ventilation in survivors of acute hypercapnic respiratory failure in COPD. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A767. ">Cheung 2010</a>; <a href="./references#CD002878-bbs2-0010" title="GayPC , HubmayrRD , StroetzRW . Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a three-month controlled trial. Mayo Clinic Proceedings1996;71(6):533-42. ">Gay 1996</a>; <a href="./references#CD002878-bbs2-0018" title="SinDD , WongE , MayersI , LienDC , FeenyD , CheungH , et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest2007;131(1):156-63. ">Sin 2007</a>), an optimal sham treatment is not available as these approaches could increase anatomical dead space or alter respiratory mechanisms, possibly also affecting the respiratory failure (<a href="./references#CD002878-bbs2-0064" title="RodwayGW , WeaverTE , ManciniC , CaterJ , MaislinG , StaleyB , et al. Evaluation of sham-CPAP as a placebo in CPAP intervention studies. Sleep2010;33(2):260-6. [DOI: 10.1093/sleep/33.2.260]">Rodway 2010</a>; <a href="./references#CD002878-bbs2-0067" title="SaatciE , MillerDM , Stell M , LeeKC , MoxhamJ . Dynamic dead space in face masks used with noninvasive ventilators: a lung model study. European Respiratory Journal2004;23(1):129-35. [DOI: 10.1183/09031936.03.00039503]">Saatci 2004</a>). The extent to which the unblinded nature of the trials influences the outcomes differs; e.g. blood gases, hospitalisations and mortality are unlikely to be affected, whilst participant‐reported outcomes are likely affected to a larger extent. Secondly, we have also included trials investigating chronic NIV applied during the night in addition to a training or rehabilitation program. It is, however, difficult to study the additional benefit of these training programs as for the majority of the included studies, it was unclear if participants were allowed to follow such a program, as studies did not record this adequately. Third, data on the actual timing of NIV initiation were missing in the post‐exacerbation trials. This data would be of value to estimate the optimal timing of chronic NIV initiation shortly following an episode of AHRF. Fourth, exacerbations and hospitalisation frequency proved difficult to investigate adequately. Many studies did not report these numbers prior to trial inclusion, pre‐study numbers were not always objectively assured and so could have been affected by recall bias, or studies reported exacerbations and hospitalisations over a different time frame (e.g. one or three years). It was therefore difficult to investigate whether NIV actually reduced the number of exacerbations. Additionally, nine of the included studies investigated HRQL but used multiple tools to assess this. We chose to consider only the disease‐specific SRI and the SGRQ, as these tools have shown good validity and reliability, especially in people with COPD in a stable phase (<a href="./references#CD002878-bbs2-0068" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. The Severe Respiratory Insufficiency Questionnaire scored best in the assessment of health-related quality of life in chronic obstructive pulmonary disease. Journal of Clinical Epidemiology2013;66(10):1166-74. [DOI: 10.1016/j.jclinepi.2013.04.013]">Struik 2013</a>). We therefore recommend future trials to use disease‐specific HRQL tools such as the SRI. Lastly, one trial only reported the percentage predicted values of the lung function outcomes. Using the regression equations, we were able to calculate the absolute values, but we acknowledge that this could introduce uncertainty and is sensitive to errors. </p> </section> </section> <section id="CD002878-sec-0123"> <h3 class="title" id="CD002878-sec-0123">Agreements and disagreements with other studies or reviews</h3> <p>In recent years, two systematic reviews and meta‐analyses have been conducted. Inclusion criteria appear similar to our review, except that both these reviews included observational or non‐RCTs, and also included trials that compared different NIV strategies. Comparison of mortality and admission outcomes is difficult, as no review has been published that studied these outcomes as time‐to‐event data. </p> <p>Recently, a systematic review and meta‐analysis was published that included 51,085 people with COPD who experience chronic hypercapnia(33 studies), investigating the effect of chronic home NIV on mortality, all‐cause hospital admissions and quality of life (<a href="./references#CD002878-bbs2-0074" title="WilsonME , DoblerCC , MorrowAS , BeuschelB , AlsawasM , BenkhadraR , et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of the American Medical Association2020;323(5):455-65. [DOI: 10.1001/jama.2019.22343]">Wilson 2020</a>). As compared to our systematic review, this review included both RCTs and observational studies, and did not differentiate according to the timing of NIV initiation. However, the review authors also conducted subgroup analysis based on the timing of NIV initiation. These results are, in general, consistent with our finding; a significantly lower mortality risk (OR 0.62, 95% CI 0.42 to 0.92) and no effect on hospital admissions (RR 0.84, 95% CI 0.59 to 1.18) for people initiated in a stable phase, and no significant effect on mortality (OR 0.66, 95% CI 0.41 to 1.06) or HRQL (standardised MD ‐0.03, 95% CI ‐0.25 to 0.20) in people initiated following an acute exacerbation. They did not find a beneficial effect on HRQL in the stable subgroup. This difference might be explained by the tools used in the review by <a href="./references#CD002878-bbs2-0074" title="WilsonME , DoblerCC , MorrowAS , BeuschelB , AlsawasM , BenkhadraR , et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of the American Medical Association2020;323(5):455-65. [DOI: 10.1001/jama.2019.22343]">Wilson 2020</a>; the COPD assessment test, the Chronic Respiratory disease Questionnaire, the SGRQ and the Short‐form 36. HRQL tools designed specifically for people with respiratory failure, such as the SRI that was used for this review, might be more sensitive to change (<a href="./references#CD002878-bbs2-0068" title="StruikFM , KerstjensHA , BladderG , SprootenR , ZijnenM , AsinJ , et al. The Severe Respiratory Insufficiency Questionnaire scored best in the assessment of health-related quality of life in chronic obstructive pulmonary disease. Journal of Clinical Epidemiology2013;66(10):1166-74. [DOI: 10.1016/j.jclinepi.2013.04.013]">Struik 2013</a>). In addition, we have also used the HRQL data of the RCTs of <a href="./references#CD002878-bbs2-0004" title="CliniE , SturaniC , RossiA , ViaggiS , CorradoA , DonnerCF , et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. European Respiratory Journal2002;3:529-38. CliniE , SturaniC . A multicentric long-term study of noninvasive pressure support ventilation (NSPV) in hypercapnic COPD patients. In: European Respiratory Journal. Vol. 12. 1998:297S. ">Clini 2002</a> and <a href="./references#CD002878-bbs2-0014" title="McEvoyRD , PierceRJ , HillmanD , EstermanA , EllisEE , CatchesidePG , et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax2009;64(7):561-6. ">McEvoy 2009</a>, which could explain the observed difference. </p> <p>In 2016, <a href="./references#CD002878-bbs2-0045" title="DretzkeJ , MooreD , DaveC , MukherjeeR , PriceMJ , BaylissS , et al. The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalised patients with COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11:2269-86. [DOI: 10.2147/COPD.S104238]">Dretzke 2016</a> published their systematic review of both RCTs and non‐RCTs (31 studies), also grouping studies into stable and post‐exacerbation populations. When the  <a href="./references#CD002878-bbs2-0045" title="DretzkeJ , MooreD , DaveC , MukherjeeR , PriceMJ , BaylissS , et al. The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalised patients with COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11:2269-86. [DOI: 10.2147/COPD.S104238]">Dretzke 2016</a> review was published, some large trials included in the present review had not yet been published (<a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>; <a href="./references#CD002878-bbs2-0021" title="NCT02499718. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT02499718 (first received 16 July 2015). ZhouL ,  LiX , GuanL , ChenJ , GuoB , WuW , et al. Home noninvasive positive pressure ventilation with built-in software in stable hypercapnic COPD: a short-term prospective, multicenter, randomized, controlled trial. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1279-86. ">Zhou 2017</a>), possibly explaining the observed differences. They did not find a survival benefit of NIV in either the stable participants (RR 0.88, 95% CI 0.55 to 1.43) or the post‐exacerbation population (RR 0.89, 95% CI 0.53 to 1.49). Results on the blood gases were not included in the meta‐analysis but support our findings as they suggest improved blood gases (PaCO<sub>2</sub> and PaO<sub>2</sub>) in the stable population, and a potential benefit on PaCO<sub>2</sub> in the post‐exacerbation cohort. </p> <p>Lastly, the results of our review on COPD exacerbation in the post‐exacerbation cohort contradict a major finding of <a href="./references#CD002878-bbs2-0016" title="MurphyP , ArbaneG , BourkeS , CalverleyP , DowsonL , DuffyN , et al. Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: hoT-HMV UK Trial NCT00990132. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. MurphyPB , ArbaneG , BisqueraA , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: predicting 1 year admission-free survival in the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A26-7. MurphyPB , ArbaneG , BourkeS , CalverleyP , CrooksA , DowsonL , et al. Hot-HMV UK trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in COPD patients with chronic respiratory failure following a life-threatening exacerbation. Thorax2016;71:A68-9. [DOI: 10.1136/thoraxjnl-2016-209333.121]MurphyPB , ArbaneG , PatoutM , HartN . Results from UK HOT-HMV Trial: clinical importance of recovery of hypercapnia following acute life-threatening exacerbation of COPD. European Respiratory Journal2018;52((suppl 62)):PA1679. [DOI: 10.1183/13993003.congress-2018.PA1679]MurphyPB , ArbaneG , PhillipsR , HartN . Home mechanical ventilation (HMV) and home oxygen therapy (HOT) following an acute exacerbation of COPD in patients with persistent hypercapnia: results of the per protocol analysis from the hot-HMV UK trial. In: British Thoracic Society Winter Meeting; 2017 Dec 6–8; London. Vol. Supplement 3. 2017:A25-A6. MurphyPB , RehalS , ArbaneG ,   BourkeS , CalverleyPM , CrookAM , et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. Journal of the American Medical Association2017;317(21):2177-86. ">Murphy 2017</a>, who found a reduced exacerbation rate favouring the NIV group. In contrast to Murphy, we conducted our analysis only on participants who completed the 12‐month follow‐up ('completers'). Dropouts could be unequally distributed between both study arms, and the 'time at risk' for an exacerbation could therefore differ between both arms, introducing bias. Although including only completers reduced statistical power, there was not even a trend towards a reduced exacerbation rate in our analysis. We acknowledge that this analysis setup could explain the observed difference. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002878-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD002878-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each methodological quality item for each included studyNote: blank squares indicate that the outcome domain was not measured in the study." data-id="CD002878-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each methodological quality item for each included study </p> <p>Note: blank squares indicate that the outcome domain was not measured in the study.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-03" target="_blank"><b></b></a></p> </div><img alt="The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in stable COPDBlack triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL." data-id="CD002878-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in stable COPD </p> <p>Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for the PaO2 outcome after 3 months, in participants with stable COPD" data-id="CD002878-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for the PaO<sub>2</sub> outcome after 3 months, in participants with stable COPD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-05" target="_blank"><b></b></a></p> </div><img alt="The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in post‐exacerbation COPD Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL." data-id="CD002878-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>The modelled means of the adjusted mixed‐effect models for the primary outcomes, separate for the NIV and the control group, in post‐exacerbation COPD  </p> <p>Black triangles: NIV group; red squares: control group. * indicates that the 95% confidence interval of the treatment effect does not cross zero. For the HRQL outcome, a positive value indicates improved HRQL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD002878-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-FIG-07" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD002878-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 1: Stable COPD: PaO2" data-id="CD002878-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 1: Stable COPD: PaO<sub>2</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 2: Stable COPD: PaCO2" data-id="CD002878-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 2: Stable COPD: PaCO<sub>2</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 3: Stable COPD: 6‐minute walking distance" data-id="CD002878-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 3: Stable COPD: 6‐minute walking distance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 4: Stable COPD: HRQL" data-id="CD002878-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 4: Stable COPD: HRQL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 5: Stable COPD: FEV1" data-id="CD002878-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 5: Stable COPD: FEV<sub>1</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 6: Stable COPD: FVC" data-id="CD002878-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 6: Stable COPD: FVC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 7: Stable COPD: RV/%TLC" data-id="CD002878-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 7: Stable COPD: RV/%TLC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 8: Stable COPD: PEmax" data-id="CD002878-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 8: Stable COPD: PEmax </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 9: Stable COPD: PImax" data-id="CD002878-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 9: Stable COPD: PImax </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 10: Stable COPD: Transition Dyspnoea Index" data-id="CD002878-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 10: Stable COPD: Transition Dyspnoea Index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 11: Stable COPD: (modified) Medical Research Council dyspnoea scale" data-id="CD002878-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 11: Stable COPD: (modified) Medical Research Council dyspnoea scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 12: Stable COPD: sleep efficiency" data-id="CD002878-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 12: Stable COPD: sleep efficiency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 13: Stable COPD: exacerbations" data-id="CD002878-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 13: Stable COPD: exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 14: Stable COPD: hospitalisations" data-id="CD002878-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 14: Stable COPD: hospitalisations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 15: Stable COPD: all‐cause mortality" data-id="CD002878-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 15: Stable COPD: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 16: PaCO2 after 3 months ‐ subgroup PaCO2 (stable COPD)" data-id="CD002878-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 16: PaCO<sub>2 </sub>after 3 months ‐ subgroup PaCO<sub>2</sub> (stable COPD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 17: PaCO2 after 3 months ‐ subgroup IPAP (stable COPD)" data-id="CD002878-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 17: PaCO<sub>2 </sub>after 3 months ‐ subgroup IPAP (stable COPD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 18: PaCO2 after 3 months ‐ subgroup compliance (stable COPD)" data-id="CD002878-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: NIV vs standard care in stable COPD, Outcome 18: PaCO<sub>2 </sub>after 3 months ‐ subgroup compliance (stable COPD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 1: Post‐exacerbation COPD: PaO2" data-id="CD002878-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 1: Post‐exacerbation COPD: PaO<sub>2</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 2: Post‐exacerbation COPD: PaCO2" data-id="CD002878-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 2: Post‐exacerbation COPD: PaCO<sub>2</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 3: Post‐exacerbation COPD: HRQL" data-id="CD002878-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 3: Post‐exacerbation COPD: HRQL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 4: Post‐exacerbation COPD: admission‐free survival" data-id="CD002878-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 4: Post‐exacerbation COPD: admission‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 5: Post‐exacerbation COPD: FEV1" data-id="CD002878-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 5: Post‐exacerbation COPD: FEV<sub>1</sub> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 6: Post‐exacerbation COPD: FVC" data-id="CD002878-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 6: Post‐exacerbation COPD: FVC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 7: Post‐exacerbation COPD: exacerbations" data-id="CD002878-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 7: Post‐exacerbation COPD: exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 8: Post‐exacerbation COPD: hospitalisations" data-id="CD002878-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 8: Post‐exacerbation COPD: hospitalisations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002878-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/urn:x-wiley:14651858:media:CD002878:CD002878-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 9: Post‐exacerbation COPD: all‐cause mortality" data-id="CD002878-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_t/tCD002878-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: NIV vs standard care in post‐exacerbation COPD, Outcome 9: Post‐exacerbation COPD: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/media/CDSR/CD002878/image_n/nCD002878-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002878-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : stable COPD <b>Setting</b> : home treatment <b>Intervention</b> : NIV <b>Comparison</b>: Standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NIV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>‐0.07</b> kPa <sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.27 kPa higher</b><br/>(0.04 higher to 0.49 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV probably results in a slightly greater increase in arterial partial pressure of oxygen after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>‐0.06</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.09 kPa higher</b><br/>(0.23 lower to 0.42 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may result in little to no difference in arterial partial pressure of oxygen after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.17</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.61 kPa lower</b><br/>(0.77 lower to 0.45 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>475<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in the arterial partial pressure of carbon dioxide after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.05</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.42 kPa lower</b><br/>(0.68 lower to 0.16 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in arterial partial pressure of carbon dioxide after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in 6‐minute walking distance<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in 6‐minute walking distance was <b>16.0</b> metres </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>15.5 metres higher</b><br/>(0.8 lower to 31.7 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>330<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>d,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence suggests that chronic NIV results in little to no difference on the 6‐minute walking distance test. Sensitivity analysis limited to high‐quality studies suggest a significant benefit; however, this treatment estimate does not reach the minimal important difference of 26m. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in 6‐minute walking distance<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in 6‐minute walking distance was <b>‐10.7</b> metres </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>26.4 metres higher</b><br/>(7.6 lower to 60.5 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>g,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase the 6‐minute walking distance but the evidence is very uncertain. This treatment estimate reaches the clinical relevance of 26m in this specific population. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 3 months <sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.39 SD higher</b><br/>(0.15 higher to 0.62 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>d,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase health‐related quality of life after 3 months but the evidence is very uncertain. Considering the standard deviation of 12 units on the SRI, the observed SMD does seem to reach the minimal important difference of approximately 5 points in this specific population. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 12 months <sup>i</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.15 SD higher</b><br/>(0.13 lower to 0.43 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>h,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence is very uncertain about the effect of chronic NIV on health‐related quality of life after 12 months. Considering a standard deviation of 12.2 units on the SRI, the observed SMD does not seem to reach the minimal important difference of approximately 5 points. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality<br/>follow up: median 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.75</b><br/>(0.58 to 0.97)<br/>[All‐cause mortality] <sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>405<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Chronic NIV likely reduces all‐cause mortality (number needed to treat for an additional beneficial outcome 14, 95% CI 8 to 120). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>655 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>550 per 1000</b><br/>(461 to 644) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>SMD:</b> Standardised mean difference; <b>HR:</b> Hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417569665332318026" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417569665332318026</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> For the risk with standard care, we calculated an absolute difference in the outcome between the baseline measurement and both follow‐up measurements (3 and 12 months)<br/><b>b.</b> The mean difference was obtained from the pooled individual participant data, and was adjusted for age and sex. <br/><b>c.</b> Not downgraded; although the participants and investigators were not blinded in the majority of the trials, this is unlikely to affect blood gases and survival.<br/><b>d.</b> Downgraded by one for serious imprecision; the CI includes the possibility of no (relevant) benefit and of a substantial benefit.<br/><b>e.</b> Downgraded by one due to serious imprecision: the CI includes the possibility of harm and of a large substantial benefit. <br/><b>f.</b> Inconsistency not downgraded; although substantial heterogeneity was observed (P = 0.001, I2 = 65%), this could be explained by the subgroup analysis.<br/><b>g.</b> Downgraded by one due to high risk of bias; the majority of the trials did not blind participants and investigators/personnel to the treatment allocation.<br/><b>h.</b> Downgraded by two due to serious imprecision: the CI includes the possibility of harm and of a large substantial benefit. <br/><b>i.</b> SRI: Severe Respiratory Insufficiency questionnaire; SGRQ: St. George's Respiratory Questionnaire<br/><b>j.</b> Downgraded by one due to high risk of bias; no trials blinded participants and investigators/personnel to the treatment allocation.<br/><b>k.</b> The hazard ratio was obtained from the pooled individual participant data, and was adjusted for age, sex and the baseline arterial pressure of carbon dioxide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment for people with stable COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002878-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : post‐exacerbation COPD <b>Setting</b> : home treatment <b>Intervention</b> : NIV <b>Comparison</b>: Standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with Standard care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with NIV</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>0.19</b> kPa <sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.1 kPa lower</b><br/>(0.65 lower to 0.45 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The evidence suggests that chronic NIV results in little to no difference in arterial partial pressure of oxygen after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of oxygen<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of oxygen was <b>0.48</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.27 kPa lower</b><br/>(0.86 lower to 0.32 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may result in a slight reduction in arterial partial pressure of oxygen after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.59</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.4 kPa lower</b><br/>(0.7 lower to 0.09 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV likely reduces the arterial partial pressure of carbon dioxide after 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in arterial partial pressure of carbon dioxide<br/>follow up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in arterial partial pressure of carbon dioxide was <b>‐0.61</b> kPa </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>0.52 kPa lower</b><br/>(0.87 lower to 0.18 lower) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV results in a reduction in the arterial partial pressure of carbon dioxide after 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 3 months <sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.25 SD higher</b><br/>(0.01 lower to 0.51 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase/have little to no effect on health‐related quality of life after 3 months but the evidence is very uncertain. Considering a standard deviation of 11.2 on the SRI, the SMD does not seem to reach the minimal important difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in the health‐related quality of life<br/>assessed with: SRI and SGRQ<br/>follow up: 12 months <sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>SMD <b>0.25 SD higher</b><br/>(0.06 lower to 0.55 higher) <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>e,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic NIV may increase/have little to no effect on health‐related quality of life after 12 months but the evidence is very uncertain. Considering a standard deviation of 11.9 on the SRI, the SMD does not seem to reach the minimal important difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Admission‐free survival<br/>follow up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.71</b><br/>(0.54 to 0.94)<br/>[readmission or death] <sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>317<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>e,</sup><sup>i,</sup><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The evidence suggests chronic NIV improves admission‐free survival (number needed to treat for an additional beneficial outcome 12, 95% CI 7 to 61). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>458 per 1000</b><br/>(356 to 552) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality<br/>follow up: median 21 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.97</b><br/>(0.74 to 1.28)<br/>[All‐cause mortality] <sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>318<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The evidence suggests that chronic NIV does not improve all‐cause mortality.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>642 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>631 per 1000</b><br/>(532 to 731) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>SMD:</b> Standardised mean difference; <b>HR:</b> Hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417570213828006491" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_417570213828006491</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> For the risk with standard care, we calculated an absolute difference in the outcome between the baseline measurement and both follow‐up measurements (3 and 12 months).<br/><b>b.</b> The mean difference was obtained from the pooled individual participant data, and was adjusted for age and sex.<br/><b>c.</b> Not downgraded; although the participants and investigators were not blinded in the majority of the trials, this is unlikely to affect blood gases and survival.<br/><b>d.</b> Downgraded by two due to serious imprecision: the CI includes the possibility of significant harm and of a substantial benefit.<br/><b>e.</b> Downgraded by one due to serious imprecision: the CI includes the possibility of no (relevant) benefit and of a substantial benefit.<br/><b>f.</b> SRI: Severe Respiratory Insufficiency questionnaire; SGRQ: St. George's Respiratory Questionnaire<br/><b>g.</b> Downgraded by two due to high risk of bias; no trials blinded participants and investigators/personnel to the treatment allocation.<br/><b>h.</b> The hazard ratio was obtained from the pooled individual participant data, and was adjusted for age sex, baseline arterial partial pressure of carbon dioxide and number of COPD hospitalisations. <br/><b>i.</b> Downgraded by one; the majority of the participants were unblinded which could affect the likelyhood of attending the emergency department. Other domains low risk of bias<br/><b>j.</b> Inconsistency not downgraded; although substantial heterogeneity was observed (P = 0.05, I2 = 75%), this heterogeneity might be explained by differences in participant selection and the timing of NIV. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ Chronic non‐invasive ventilation compared to standard treatment following a severe exacerbation for people with severe COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002878-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in stable COPD, separate for the NIV and the control group</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>3 months</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>12 months</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Change in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaO<sub>2</sub> </b> (kPa) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17 ± 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 ± 0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 ± 1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.06 ± 1.12</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaCO<sub>2</sub> </b> (kPa) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.81 ± 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.17 ± 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.46 ± 1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 0.98</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6MWD</b> (m) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.2 ± 73.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 75.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 105.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.7 ± 94.8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SRI,</b> summary score </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 ± 14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 ± 9.3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SGRQ,</b> total score </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.2 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 ± 8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 ± 14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.9 ± 15.3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> </b> (l) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 ± 0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 ± 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 ± 0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 ± 0.15</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FVC </b>(l) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 ± 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 ± 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 ± 0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 0.46</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RV/TLC</b> (%) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.6 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.05 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 ± 8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 ± 9.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PEmax </b>(cmH<sub>2</sub>O) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7 ± 24.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 ± 23.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 ± 46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 36.1</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PImax</b> (cmH<sub>2</sub>O) </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 16.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 ± 16.5</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>TDI</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>(m)MRC</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.7 ± 1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.4 ± 0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.6 ± 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.1 ± 1.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sleep efficiency</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 ± 16.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>COPD exacerbations</b><sup>a</sup> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0 to 1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0 to 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.8 to 4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.0 to 5.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>COPD hospitalisations</b><sup>a</sup> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 2.0)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Data are based on the studies that provided the IPD, and are presented as mean ± standard deviation or median (interquartile range). <br/><sup>a</sup> absolute number of exacerbations or hospitalisations. </p> <p>6MWD: 6‐minute walking distance; CI: confidence interval; COPD: Chronic Obstructive Pulmonary Disease; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; (m)MRC: (modified) Medical Research Council dyspnoea scale, a decrease indicates an improvement in dyspnoea; NIV: noninvasive ventilation; PaCO<sub>2</sub>: arterial carbon dioxide tension; PaO<sub>2</sub>: arterial oxygen tension; PEmax: peak expiratory pressure; PImax: peak inspiratory pressure; RV/TLC: residual volume/total lung capacity; SGRQ: St. George's Respiratory Questionnaire, a decrease indicates an improved health‐related quality of life; SRI: Severe Respiratory Insufficiency questionnaire, an increase indicates an improved health‐related quality of life; TDI: transitional dyspnoea index, a positive value indicates an improvement in dyspnoea. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in stable COPD, separate for the NIV and the control group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002878-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in post‐exacerbation COPD, separate for the NIV and the control group</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>3 months</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>12 months</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in NIV group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in control group</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaO<sub>2</sub> (kPa)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.08 ± 2.33 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.19 ± 2.12 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.21 ± 1.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.48 ± 2.10 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PaCO<sub>2</sub> (kPa)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.99 ± 1.24 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.59 ± 1.19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐1.12 ± 1.15 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.61 ± 1.20 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>SRI, summary score</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4.7 ± 10.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.7 ± 11.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4.8 ± 11.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.7 ± 11.8 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> (l)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.02 ± 0.19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.04 ± 0.20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.01 ± 0.21 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.03 ± 0.22 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FVC (l)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.01 ± 0.66 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.12 ± 0.63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>‐0.01 ± 0.64 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.08 ± 0.68 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>COPD exacerbations <sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 [0 to 1.0]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 [0 to 1.0] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.0 [1.0 to 4.0]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2.0 [1.0 to 4.0] </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>COPD hospitalisations <sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 (0 to 2.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0 (0 to 2.0)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Data are based on the studies that provided the IPD, and are presented as mean ± standard deviation or median (interquartile range).  </p> <p><sup>a</sup> absolute number of exacerbations or hospitalisations. </p> <p>CI: confidence interval; COPD: Chronic Obstructive Pulmonary Disease; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; NIV: noninvasive ventilation; PaCO<sub>2</sub>: arterial carbon dioxide tension; PaO<sub>2</sub>: arterial oxygen tension; SRI: Severe Respiratory Insufficiency questionnaire, an increase indicates an improved health‐related quality of life. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Absolute changes in the outcomes after three and 12 months in post‐exacerbation COPD, separate for the NIV and the control group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/full#CD002878-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002878-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: NIV vs standard care in stable COPD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Stable COPD: PaO<sub>2</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.14, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.37, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Stable COPD: PaCO<sub>2</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.68, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Stable COPD: 6‐minute walking distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.85 [‐5.52, 21.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.50 [‐3.03, 50.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Stable COPD: HRQL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.24, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Stable COPD: FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.04, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Stable COPD: FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Stable COPD: RV/%TLC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐2.77, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐1.98, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Stable COPD: PEmax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.03 [‐1.51, 19.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐23.70, 30.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Stable COPD: PImax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.96 [3.29, 10.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.04 [‐12.29, 26.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Stable COPD: Transition Dyspnoea Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.01, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Stable COPD: (modified) Medical Research Council dyspnoea scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.59, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.90, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Stable COPD: sleep efficiency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.86 [‐8.76, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Stable COPD: exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.34, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.25, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Stable COPD: hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.46, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Stable COPD: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.58, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 PaCO<sub>2 </sub>after 3 months ‐ subgroup PaCO<sub>2</sub> (stable COPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Baseline PaCO2 &lt;7.3 kPa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.43, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Baseline PaCO2 ≥7.3 kPa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.10, ‐0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 PaCO<sub>2 </sub>after 3 months ‐ subgroup IPAP (stable COPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 mean IPAP &lt;18 cmH2O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.45, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 mean IPAP ≥18 cmH2O</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.12, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 PaCO<sub>2 </sub>after 3 months ‐ subgroup compliance (stable COPD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Mean compliance &lt;5 hours per night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.50, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Mean compliance ≥5 hours per night</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.84, ‐0.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: NIV vs standard care in stable COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002878-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: NIV vs standard care in post‐exacerbation COPD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Post‐exacerbation COPD: PaO<sub>2</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.58, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.81, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Post‐exacerbation COPD: PaCO<sub>2</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.72, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.88, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Post‐exacerbation COPD: HRQL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.04, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Post‐exacerbation COPD: admission‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.39, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Post‐exacerbation COPD: FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.09, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.09, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Post‐exacerbation COPD: FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.30, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.32, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Post‐exacerbation COPD: exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 follow‐up: 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.48, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Post‐exacerbation COPD: hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 follow‐up: 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.19, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Post‐exacerbation COPD: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: NIV vs standard care in post‐exacerbation COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002878.pub3/references#CD002878-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002878.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002878-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002878-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002878-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002878-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002878-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD002878-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002878-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002878-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD002878-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002878-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002878-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002878\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002878\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002878\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002878\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002878\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002878.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002878.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002878.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002878.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002878.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728463247"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002878.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728463251"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002878.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec517381a9367',t:'MTc0MDcyODQ2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 